Check for updates
Overview of the 2022 WHO Classification of Adrenal Cortical Tumors
Ozgur Mete1,2,3(D . Lori A. Erickson4D . C. Christofer Juhlin5,6D . Ronald R. de Krijger7D . Hironobu Sasano&D. Marco Volante9 . Mauro G. Papotti 10D
Accepted: 12 February 2022 / Published online: 14 March 2022 @ The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022
Abstract
The new WHO classification of adrenal cortical proliferations reflects translational advances in the fields of endocrine pathology, oncology and molecular biology. By adopting a question-answer framework, this review highlights advances in knowledge of histological features, ancillary studies, and associated genetic findings that increase the understanding of the adrenal cortex pathologies that are now reflected in the 2022 WHO classification. The pathological correlates of adrenal cortical proliferations include diffuse adrenal cortical hyperplasia, adrenal cortical nodular disease, adrenal cortical adenomas and adrenal cortical carcinomas. Understanding germline susceptibility and the clonal-neoplastic nature of individual adrenal cortical nodules in primary bilateral macronodular adrenal cortical disease, and recognition of the clonal-neoplastic nature of incidentally discovered non-functional subcentimeter benign adrenal cortical nodules has led to redefining the spectrum of adrenal cortical nodular disease. As a consequence, the most significant nomenclature change in the field of adrenal cortical pathology involves the refined classification of adrenal cortical nodular disease which now includes (a) sporadic nodular adrenocortical disease, (b) bilateral micronodular adrenal cortical disease, and (c) bilateral macronodular adrenal cortical disease (formerly known primary bilateral macronodular adrenal cortical hyperplasia). This group of clinicopathological entities are reflected in functional adrenal cortical pathologies. Aldosterone producing cortical lesions can be unifocal or multifocal, and may be bilateral with no imaging-detected nodule(s). Furthermore, not all grossly or radiologically identified adrenal cortical lesions may be the source of aldosterone excess. For this reason, the new WHO classification endorses the nomenclature of the HISTALDO classification which uses CYP11B2 immunohistochemistry to identify functional sites of aldosterone production to help predict the risk of bilateral disease in primary aldosteronism. Adrenal cortical carcinomas are subtyped based on their morphological features to include conventional, oncocytic, myxoid, and sarcomatoid subtypes. Although the classic histopathologic criteria for diagnosing adrenal cortical carcinomas have not changed, the 2022 WHO classification underscores the diagnostic and prognostic impact of angioinvasion (vascular invasion) in these tumors. Micro- scopic angioinvasion is defined as tumor cells invading through a vessel wall and forming a thrombus/fibrin-tumor complex or intravascular tumor cells admixed with platelet thrombus/fibrin. In addition to well-established Weiss and modified Weiss scoring systems, the new WHO classification also expands on the use of other multiparameter diagnostic algorithms (reticulin algorithm, Lin-Weiss-Bisceglia system, and Helsinki scoring system) to assist the workup of adrenal cortical neoplasms in adults. Accordingly, conventional carcinomas can be assessed using all multiparameter diagnostic schemes, whereas onco- cytic neoplasms can be assessed using the Lin-Weiss-Bisceglia system, reticulin algorithm and Helsinki scoring system. Pediatric adrenal cortical neoplasms are assessed using the Wieneke system. Most adult adrenal cortical carcinomas show>5 mitoses per 10 mm2 and> 5% Ki67. The 2022 WHO classification places an emphasis on an accurate assessment of tumor proliferation rate using both the mitotic count (mitoses per 10 mm2) and Ki67 labeling index which play an essential role in the dynamic risk stratification of affected patients. Low grade carcinomas have mitotic rate of ≤ 20 mitoses per 10 mm2, whereas high-grade carcinomas show > 20 mitoses per 10 mm2. Ki67-based tumor grading has not been endorsed in the new WHO classification, since the proliferation indices are continuous variables rather than being static thresholds in tumor biology. This new WHO classification emphasizes the role of diagnostic and predictive biomarkers in the workup of adrenal cortical neoplasms. Confirmation of the adrenal cortical origin of a tumor remains a critical requirement when dealing with non-functional lesions in the adrenal gland which may be mistaken for a primary adrenal cortical neoplasm. While SF1 is the most reliable biomarker in the confirmation of adrenal cortical origin, paranuclear IGF2 expression is a useful biomarker
in the distinction of malignancy in adrenal cortical neoplasms. In addition to adrenal myelolipoma, the new classification of adrenal cortical tumors has introduced new sections including adrenal ectopia, based on the potential role of such ectopic tissue as a possible source of neoplastic proliferations as well as a potential mimicker of metastatic disease. Adrenal cysts are also discussed in the new classification as they may simulate primary cystic adrenal neoplasms or even adrenal cortical carcinomas in the setting of an adrenal pseudocyst.
Keywords Adrenal cortical adenoma · Adrenal cortical carcinoma · Adrenal cortical hyperplasia · Adrenal cortical nodular disease · Primary bilateral macronodular adrenal cortical hyperplasia · IGF2 . Primary aldosteronism . Cushing syndrome · Virilization and feminization · Adrenal incidentaloma · Reticulin algorithm · Reticulin histochemistry · Lynch syndrome · WHO classification · Biomarkers
Introduction
The new WHO classification of adrenal cortical prolifera- tions reflects translational advances in the fields of endocrine pathology, endocrine oncology, and molecular biology and recognizes the importance of structural and functional corre- lations. A group of clinicopathological entities are reflected in functional and non-functional adrenal cortical patholo- gies. By adopting a practical question-answer framework, this review highlights advances in knowledge of histological features, ancillary studies, and associated genetic findings that increase the understanding of adrenal cortex patholo- gies that are now reflected in the 2022 WHO classification.
Question 1: Are There Any Nomenclature Changes or Any New Diagnostic Categories in the New WHO Classification of Adrenal Cortical Proliferations?
The pathological correlates of adrenal cortical proliferations include diffuse adrenal cortical hyperplasia, adrenal corti- cal nodular disease, adrenal cortical adenomas and adrenal cortical carcinomas [1].
In the new 5th edition of the WHO classification of adrenal cortical disease, the most significant nomenclature change in adrenal cortical pathology is the refined clas- sification of adrenal cortical nodular disease (Fig. 1). The 2022 WHO classification no longer endorses the use of “nodular adrenal cortical hyperplasia” for incidentally dis- covered sporadic non-functional adrenal cortical nodules. The latter stems from recognition of the clonal/neoplastic nature of incidentally discovered non-functional subcen- timeter benign adrenal cortical nodules [1-5]. The new classification endorses the term sporadic nodular adreno- cortical disease for such manifestations (Fig. 2). Historical terms of primary bilateral micronodular or macronodular adrenocortical hyperplasia are no longer used as the nod- ules are independent clonal proliferations and referred to as bilateral micro- or macro-nodular adrenal cortical disease
and classified among benign adrenal cortical tumors [1-5]. Virtually all bilateral micronodular and a significant frac- tion of bilateral macronodular adrenal cortical diseases are caused by genetic susceptibility [4-14]. These findings have resulted in redefining the clinicopathologic spectrum of adrenal cortical nodular disease. Consistently, the new WHO classification subtypes adrenal cortical nodular dis- ease as: (a) sporadic nodular adrenocortical disease, (b) bilateral micronodular adrenal cortical disease, and (c) bilateral macronodular adrenal cortical disease (Fig. 1). The distinction between these diagnostic categories reflects diverse clinical manifestations [4, 5, 15].
In the 2022 WHO classification, apart from diffuse compact cell adrenal cortical hyperplasia identified in adrenal glands and adrenal rests from patients with congenital adrenal hyperplasia, the diagnostic category of adrenal cortical hyperplasia is now restricted to bilateral diffuse adrenal cortical hyperplasia, which can be driven by a pituitary corticotroph tumor (corticotroph pituitary neuroendocrine tumor) or hypothalamic neoplasms or ectopically with ACTH- or CRH-dependent pathogenesis (e.g., ACTH- or CRH-producing neuroendocrine neoplasm, paraganglioma) [1, 15]. Pituitary ACTH-dependent diffuse adrenal cortical hyperplasia results in diffuse expansion of the adrenal cortex in both adrenal glands with preserved adrenal cortical zonation [15], while ectopic ACTH-driven adrenal cor- tical hyperplasia lacks distinct adrenal cortical zonation due to diffuse compact cell hyperplasia resulting in a pink appearance to the adrenal cortices due to lipid depletion [15].
Another significant change in the new WHO classifica- tion is the pathologic evaluation of adrenal glands removed for primary aldosteronism. As primary aldosteronism may be due to a single lesion or multiple lesions involving one or both adrenal glands, the new WHO classification endorses the nomenclature of the HISTALDO classification (Fig. 3), which uses CYP11B2 immunohistochemistry to identify functional sites of aldosterone production which help predict the risk of bilateral disease in primary aldosteronism [16-21].
The new WHO bluebook also covers three new separate chapters on adrenal cysts, adrenal ectopia, and myelolipoma. The details of most of the new sections and other updates are discussed in questions of this review.
Adrenocortical nodular disease
Sporadic nodular adrenocortical disease
Bilateral micronodular adrenocortical disease
Bilateral macronodular adrenocortical disease
·Non-functional. ·Solitary or sparsely distributed multifocal nodules measuring < 1 cm. .Occurs in all age groups.
·Usually unilateral but may be bilateral. ·Morphologically indistinguishable from non-functional adrenal cortical adenomas measuring < 1 cm.
.Typically associated with endogenous Cushing syndrome. ·Multiple nodules < 1 cm. .Occurs in children and adults <30 years.
.Typically associated with endogenous Cushing syndrome.
·Multiple large nodules > 1 cm. .Occurs predominantly in adults.
·Bilateral involvement.
·Pathogenic germline variants activating the protein kinase A (PKA) pathway.
·Bilateral involvement. ·Pathogenic germline variants in ARMC5, MEN1, FH or APC are common.
Primary pigmented nodular adrenocortical disease (PPNAD)
Isolated micronodular adrenocortical disease (i-MAD)
·Often associated to Carney complex (c-PPNAD). ·Subsets develop outside of Carney complex (i-PPNAD).
·Multiple nodules without pigmentation. ·Germline aberrancies in PRKACA, PDE8B or PDE11A.
·Multiple pigmented nodules and internodular cortical atrophy.
·Germline variants in PRKAR1A (both c-PPNAD and i-PPNAD).
Question 2: Why Do Pathologists Need to Know Ectopic or Heterotopic Locations for Adrenal Cortical Tissue?
The 2022 WHO classification of adrenal cortical tumors has a new chapter on adrenal ectopia, based on the potential role of ectopic tissue as the source of neoplastic proliferations
as well as a potential mimicker of metastatic disease. For practicing pathologists, it is helpful to know the existence, location and main histological features of these conditions. Adrenal ectopia has been variably addressed as adrenal het- erotopia, rests, remnants or choristoma.
Adrenal ectopia is defined as isolated benign adrenal cortical tissue outside orthotopic adrenal glands. Most adrenal rests have been identified in anatomic locations that are aligned with their embryologic developmental tract. Adrenal cortical choristoma is a related term to adrenal ectopia and is defined as mature adrenal cortical elements whose location cannot be explained with the nor- mal embryogenesis of adrenal cortex. Adrenal rests may become clinically relevant when they are associated with disorders such as congenital adrenal hyperplasia. Adrenal rest tumor is a term generally restricted to nodular pro- liferations in the gonads, and it is not a term for ectopic adrenal cortical tissue.
In surgical pathology, most adrenal rests are discovered as incidental microscopic findings in various surgical speci- mens including kidneys or gonads (particularly, spermatic cord [22], rete testis [23-25], epididymis [26], ovary/parao- varian [22, 27-33], salpinx and parasalpinx [22, 34, 35] ). A recent surgical series from adults identified ectopic adre- nal rests in both males and females with a more frequent
HISTALDO classification scheme
CYP11B2 positive adrenal cortical lesions
Aldosterone producing adrenal cortical carcinoma (APACC)
Aldosterone producing adrenal cortical adenoma (APA)
Aldosterone producing nodule (APN)
Aldosterone producing micronodule (APM)
Multiple APN or APM (MAPN/MAPM)
Aldosterone producing diffuse hyperplasia (APDH)
Solitary nodule Malignant features
Solitary nodule ≥1 cm
Solitary nodule <1 cm
Solitary nodule <1 cm
Multiple nodules <1 cm
Continous staining along zona glomerulosa
☐ Seen on H&E and IHC ≥ 1 cm
Formerly known as aldosterone producing cell clusters
Formerly known as micronodular hyperplasia
☐ Seen on H&E and IHC < 1 cm Sometimes seen on ☐ H&E, seen on IHC < 1 cm
presentation in para-ovarian tissues [22]. Rare locations of adrenal rests include the placenta [36], broad ligament [22, 37, 38], retroperitoneum [39, 40], urinary bladder and pros- tate [41], groin [42, 43], choroid plexus [44], spine [45-47], and lung [48, 49]. Among various locations, adrenal cortical choristomas have also been described within TPIT-lineage pituitary neuroendocrine tumors (corticotroph PitNETs) [50, 51].
Adrenal cortical rests are characterized by small sub- centimeter, isolated, yellow nodules in the fibrofatty tissue surrounding normal components at the individual location
tifocal, these entities are termed “multiple APN” (MAPN) and “mul- tiple APM” (MAPM), respectively-corresponding to the older term “micronodular hyperplasia.” Finally, aldosterone producing diffuse hyperplasia is characterized by a continuous CYP11B2 staining along the zona glomerulosa. Image created with BioRender.com. Reproduced from Juhlin CC, Bertherat J, Giordano TJ, Hammer GD, Sasano H, Mete O. What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics. Endocr Pathol. 2021 Mar;32(1):102-133
[22-24, 52, 53]. Histologically, aggregates of large eosin- ophilic or clear cells, with no or bland atypia resembling orthotopic adrenal cortical cell populations are observed (Fig. 4). Conversely, the medullary component of the adrenal is rarely observed, and generally restricted to cases found in the ectopias surrounding normal adrenal medulla, with even rarer exceptions (e.g., a mediastinal location of functioning cortical and medullary cells) [54].
Adrenal cortical choristomas are composed of adrenal cortical cells with bland cytomorphology, and they occur either isolated or in aggregates within normal or neoplastic
A
B
cell populations (e.g., corticotroph PitNET) of the involved organ [50, 51]. The mechanism underlying their develop- ment is incompletely understood. It may be the result of misplacement of adrenal tissue far from its anatomic loca- tion during embryogenesis [50, 51]. Alternatively, at least in pituitary locations, a role of SF1 (a transcription factor implicated in both pituitary and adrenal cortex functions), might be envisaged, possibly acting on uncommitted stem cells within the sella [51].
Rarely, adrenal cortical neoplasms arise from ectopic adrenal tissues. Adenomas of adrenal cortical origin have been reported in the liver [55] and the gastric wall [56]. In
addition, prolonged hormonal hyperstimulation can induce adrenal cortical cell hyperplasia-to-neoplasia sequence and may result in “adrenal rest tumors.” Adrenal ectopic tissue must be distinguished from Leydig cell and other steroid producing gonadal tumors and non-steroidogenic neoplasms (e.g., renal cell carcinoma and hepatocellular carcinoma) [23, 24, 53, 57, 58].
Adrenal cortical rests and choristomas share immunohis- tochemical features of adrenal cortical cells as they express SF1 and other non-specific biomarkers of adrenal cortical differentiation [22, 51, 59, 60]. The distinction of adrenal cortical rest-related proliferations from other steroidogenic neoplasms poses a diagnostic challenge and may require the use of adrenal cortex-related steroidogenic enzyme immu- nohistochemistry as discussed in Question 10.
Question 3: What are the Pathological Correlates of Adrenal Cysts?
The new WHO classification has introduced a new chapter on adrenal cysts, based on their potential of simulating pri- mary cystic adrenal neoplasms or even adrenal cortical car- cinomas in the setting of an adrenal pseudocyst. For practic- ing pathologists, it is therefore relevant to be aware of their different types, main histological features and relationships with cystic neoplasms. Adrenal cysts are defined as benign, circumscribed, fluid-containing masses or nodules. They are rare with a reported incidence of 0.06% [61]. They are usu- ally detected as incidental findings at the time of imaging studies, and account for up to 4% of adrenal masses [62-65]. A slight female predilection and a mean cyst size of 7.9 cm have been reported in a review of the literature [62].
There are four distinct types of adrenal cysts: (a) pseudo- cyst, (b) endothelial (vascular cyst), (c) epithelial cyst, and (d) parasitic cyst [62, 63, 65-67] These are associated with different etiologies and pathogenetic mechanisms. The most common adrenal cysts are pseudocysts accounting for up to 80% of cases in some series and probably resulting from hemorrhagic or traumatic events of various etiologies in the adrenal area, including COVID-19-related hemorrhage [62, 63, 66]. While parasitic cysts are related to Echinococcus infections, endothelial cysts develop from dilated and throm- bosed blood or lymphatic vessels, and epithelial cysts are associated to mesothelial remnants [63]. Irrespective of the subtype and origin they may reach relevant size and mimic a tumor [62, 68, 69].
Histologically, adrenal cysts can be relatively easily clas- sified, based on the cyst wall structure. First, the presence of a cell lining is to be assessed. In its absence, an adrenal pseudocyst is considered, generally containing a fibrino- hemorrhagic fluid and delimited by a more or less thickened
fibrous tissue [62, 69] (Fig. 5). When a lining is detected, it is generally a monolayer of flat endothelial (Fig. 6) or mesothelial cells (Fig. 7). The former is related to lymphatic rather than blood endothelium and occasional intraluminal protrusions can be observed [61, 62]. The latter are flat or cuboidal mesothelial cells, devoid of atypia. Parasitic cysts can reach remarkable size [68] and contain clear fluid in single or multiple cystic spaces and a fibro-calcific wall with PAS positive parasitic membranes [68, 70, 71] (Fig. 8). The described histological features generally do not pose diag- nostic problems with neoplastic conditions, in the absence of solid areas and/or cell atypia. However, extensive sam- pling of the cyst wall is recommended to exclude an associ- ated neoplasm. This is particularly important as majority of grossly cystic adrenal glands are adrenal cortical neoplasms or pheochromocytoma with cystic hemorrhagic degenera- tion [65].
In specific instances, particularly for epithelial and endothelial cysts, immunohistochemical markers may help classify the cyst. Conventional mesothelial (calretinin, WT1) and endothelial (D2-40, CD31, ERG) markers can read- ily define the epithelial/mesothelial or endothelial origin, respectively [72] (Figs. 6 and 7). Pseudocysts and parasitic cysts generally do not require specific immunoprofiling.
Several primary and metastatic tumors in the adrenal gland may develop cystic changes, thus entering in the differential diagnosis with adrenal cysts and pseudocysts. These include cystic regressive and hemorrhagic degenera- tive changes in adrenal cortical adenoma, adrenal cortical carcinoma, pheochromocytoma, hemangioma, lymphangi- oma, angiosarcoma, vascular malformations, renal cell car- cinoma, mature teratomas, ectopic thyroid nodules, and even in metastases [62, 63, 65, 67, 73-75]. The morphological
A
B (CD31)
distinction is generally straightforward in the presence of a conventional histological component of the individual neo- plasms. However, a source of confusion is represented by the rare co-occurrence of a true cystic lesion with an adrenal neoplasm, mostly adrenal cortical adenoma [76-78], or, even more rarely, with aldosterone-producing micronodules [79].
Question 4: What are the Pathological Correlates of Adrenocortical Nodular Disease in the 2022 WHO Classification?
The new WHO classification classifies adrenocortical nodu- lar disease into 3 categories: (a) sporadic nodular adreno- cortical disease, (b) bilateral micronodular adrenocortical disease, and (c) bilateral macronodular adrenocortical dis- ease (Fig. 1). While sporadic nodular adrenocortical disease may be non-hormone producing and occur as unilateral or bilateral adrenal manifestations, the bilateral micro- and macronodular forms usually contribute to hypercortisolism and involve both adrenal glands. The latter two entities are often associated with germline variants in specific suscep- tibility genes, making them important to identify for appro- priate patient follow-up and further genetic counseling [4].
A
A
B (Calretinin)
B (PAS)
Sporadic nodular adrenocortical disease may be discov- ered incidentally via imaging in patients of all age groups and is composed of non-hormone producing adrenal cor- tical nodules measuring <1 cm [1] (Fig. 2). The underly- ing etiology is largely unknown but they likely represent non-functional adrenal cortical microadenomas. Sporadic nodular adrenal cortical disease can be solitary or multifocal with a sparse distribution. The histology is usually similar to that of non-functional adrenal cortical adenoma, and if several nodules are discovered in a patient with a known functional adenoma, the distinction of functional adrenal cortical adenoma(s) (irrespective of their size) from sporadic nodular adrenocortical disease requires functional immuno- histochemistry targeting enzymes of hormone production, such as CYP11B1, CYP11B2, and CYP17 [18, 80].
Bilateral micronodular or macronodular adrenocortical disease (Figs. 9, 10, 11, and 12) is much more infrequently observed than sporadic nodular adrenocortical disease, and it is estimated that the two former entities only account for approximately 2% of all patients with endogenous hyper- cortisolism [81, 82]. Bilateral micronodular adrenocortical nodular disease mainly occur in children and young adults, with the majority of cases being female [81-84]. Radiology
Fig. 8 Parasitic cyst: a large cyst is observed in the periadrenal adi- pose tissue, compressing the gland and containing amorphous and lamellar material (A). Manifestations restricted to the adrenal paren- chyma also occur. Parasitic membranes are better highlighted by PAS staining at higher power (B)
may underestimate the presence of bilateral adrenal gland involvement in these patients, which is probably due to the
A
1.954 mm
2mm
B
discrete nodular formations (sizes <1 cm) [1, 83] (Fig. 9). In this aspect, functional imaging using cholesterol-based scintigraphy techniques may be of value [85].
The new WHO classification describes two types of bilateral micronodular disease: (a) primary pigmented nodular adrenocortical disease (PPNAD) (Figs. 9 and 10) and (b) isolated micronodular adrenocortical dis- ease (i-MAD) [1, 4, 5, 15]. Patients with these conditions have multiple small adrenocortical nodules on histology, each measuring < 1 cm [1, 5]. These micronodules are often cortisol-producing and composed of lipid-poor cortical cells normally located to the zona fasciculata or to the zona fasciculata-reticularis junction [5]. Pri- mary pigmented adrenocortical disease (PPNAD) is
reported in most individuals with Carney complex [83, 86], and hence, this syndrome should be suspected and ruled in/out in patients with PPNAD. However, it should be stressed that except for Carney complex-associated PPNAD (entitled “c-PPNAD”), PPNAD can also occur in patients without this syndrome (denoted as “isolated PPNAD; i-PPNAD) [4, 15, 87]. The entity i-MAD is very rarely encountered in clinical practice, and the distinc- tion between i-MAD and PPNAD is based on histologi- cal findings, in which the latter entity displays multiple adrenocortical nodules with cytoplasmic pigmentation and inter-nodular cortical atrophy (Fig. 10), while the pigmentation and inter-nodular adrenal cortical atrophy are generally absent in i-MAD [4, 5, 15, 81, 88]. Most
10
20
30
40
5 0
60
70
80
90
100
150 mm
372027
1級
STAINLESS HARDENED
140
130
00 L
YAYAYO
MA
1 20
110
0 6
08
70
09
50
patients with bilateral micronodular adrenocortical dis- ease carry pathogenic germline variants in genes normally associated with the regulation of the protein kinase A (PKA) pathway involved in the physiological response to ACTH stimulation [4, 5]. For c-PPNAD and i-PPNAD, the most frequently mutated gene is PRKAR1A, whereas a subset of patients with i-PPNAD and i-MAD may exhibit constitutional PRKACA copy number gain. Moreover, individuals with i-MAD may display variants in PDE8B and PDE11A, which will also cause an increase in PKA signaling [5, 81].
Bilateral macronodular adrenocortical disease (for- merly known as “primary bilateral macronodular adrenal cortical hyperplasia”) is most often diagnosed in adults, although rare pediatric cases have been reported [4, 5, 15, 81]. More than 90% of individuals with bilateral macronod- ular adrenocortical disease have varying degrees of endog- enous hypercortisolism, but a few are non-producing [9]. Adrenal imaging usually detects massive bilateral adrenal enlargement [1, 89] (Fig. 11). Histologically, bilateral macronodular adrenocortical hyperplasia is composed of numerous nodules measuring > 1 cm each (Fig. 12). The nodules are by lipid-rich (clear) cells with occasional eosin- ophilic cells [4, 5, 15, 90]. Via next-generation sequencing studies, we now know that this entity is caused by ger- mline variants in one out of several susceptibility genes, often with a somatic-type “second hit” on the trans allele, thereby strongly arguing for a neoplastic condition rather than a “hyperplastic” disease, the latter which is a misno- mer in this aspect. Of note, constitutional ARMC5 gene variants are the most commonly reported aberration in this
context, occurring in 25-55% of cases [9, 10]. Moreover, germline variants in MEN1 (causing the multiple endocrine neoplasia type 1 syndrome) [7, 13, 91], FH (causing the hereditary leiomyomatosis and renal cell cancer syndrome) [12, 92], and APC (causing familial adenomatosis polypo- sis) [11, 12] have also been reported in individuals with bilateral macronodular adrenocortical disease. Moreover, additional somatic and/or germline gene variants have also been identified in a subset of individuals with this condition [5, 7, 8, 12, 14, 93]. Intricate molecular mechanisms, for example aberrant G-protein-coupled receptor expression or dysregulation of the ACTH receptor may explain subsets of cases [94-98].
For individuals with endogenous hypercortisolism, the new WHO classification restricts the terminology of “adre- nal cortical hyperplasia” to ACTH-dependent diffuse adre- nal cortical hyperplasia in which the cortical zonation is intact, but usually shows an expansion of the zona reticula- ris layer [1]. Since bilateral micronodular or macronodular adrenal cortical disease is a collective term describing the development of several adrenocortical lesions that often are driven by germline variants usually associated with the protein kinase A pathway, the term “hyperplasia” should be reserved for a physiological response to increased ACTH levels rather than arbitrarily used for multifocal nodules driven by clonal expansions.
Question 5: What is New in the Classification of Primary Aldosteronism in the 2022 WHO Classification of Adrenal Cortical Tumors?
Primary aldosteronism (PA) is a leading cause of sec- ondary hypertension and is characterized by aldosterone overproduction with supressed renin-angiotensin system. Hypokalemia may not occur in some patients [99]. The laboratory diagnosis of primary aldosteronism is typically based on elevated aldosterone-to-renin ratio [99].
The histopathological correlates of primary aldosteronism include (a) aldosterone-producing bilateral diffuse hyperpla- sia, (b) aldosterone-producing adrenal cortical adenomas (including microscopic nodular lesions, which can be bilat- eral and/or multifocal), and (c) aldosterone-producing adrenal cortical carcinoma [4, 100]. Aldosterone producing diffuse hyperplasia and (micro)nodules are the most common clini- cal manifestations that cause bilateral primary aldosteronism [4, 5]. Since aldosterone-producing adrenal cortical carcino- mas are exceptionally rare [101, 102], aldosterone-producing adrenal cortical adenomas are the most frequent pathologic correlates of unilateral primary aldosteronism [4, 99].
Aldosterone is produced in the zona glomerulosa by aldosterone synthase (CYP11B2, cytochrome P450 fam- ily 11, subfamily B, member 2). The production of spe- cific monoclonal antibodies against CYP11B2 [103] and its immunolocalization in resected adrenals has refined our understanding of the morphologic spectrum of this disorder [16]. This approach also helps us appreciate the link between CYP11B2-positive adrenal cortical lesions and somatic ion channel mutations leading to increased intracytoplasmic cal- cium levels that lead to autonomous CYP11B2 transcription [4, 5, 104, 105] (see Question 11).
The progress in the field of primary aldosteronism has also brought opportunities to address reporting of the his- tological entities that fall into the spectrum of aldosterone- producing adrenal cortical proliferations [16]. The recently proposed HISTALDO classification introduced a simplified approach by combining CYP11B2 immunohistochemistry and morphological findings to define clinically relevant diagnostic categories [16] (Fig. 3). This approach has been shown to predict better the risk of biochemical recurrence despite preoperative diagnostic workup [16]. The 2022 WHO classification also endorses the use of this approach to ensure accurate distinction of aldosterone-producing cor- tical lesions. The diagnostic categories in the HISTALDO classification include (a) aldosterone-producing adrenal cor- tical carcinoma (APACC), (b) aldosterone-producing adrenal cortical adenoma (APA), (c) aldosterone-producing nodule (APN), (d) aldosterone-producing micronodule (APM), (e) multifocal APN and/or APM, (f) aldosterone-producing dif- fuse hyperplasia (APDH).
Aldosterone-producing adrenal cortical carcinoma (APACC) This rare diagnostic category is applied to an adrenal cortical carcinoma that is positive for CYP11B2 [16].
Aldosterone-producing adrenal cortical adenoma (APA) APA is a CYP11B2-positive benign adrenal cortical neoplasm that measures ≥ 1 cm. It is composed of clear (zona fasciculata-like cells) and compact (zona reticularis-like) adrenal cortical cells [16] (Fig. 13).
Aldosterone-producing nodule (APN) APN is a morphologi- cally distinguished and CYP11B2-positive benign adrenal cortical lesion that measures < 1 cm (Fig. 14). This lesion
A
B (CYP11B2)
A
APN
600um
B
600um
represents a form of aldosterone-producing microadenoma at a molecular level; however, it is distinguished from APA by the gradient CYP11B2 reactivity from the external to internal fronts of the proliferation [16, 106, 107].
Aldosterone-producing micronodule (APM) (formerly known aldosterone producing cell clusters; APCC) APM is a CYP11B2-positive benign adrenal cortical lesion that measures <1 cm (often few millimetres) (Fig. 15). APMs
are composed exclusively of zona glomerulosa-like adrenal cortical cells underneath the adrenal capsule. APMs may be difficult to distinguish on hematoxylin and eosin-stained sec- tions; thus, they are typically distinguished using CYP11B2 immunohistochemistry. At a molecular level, APMs also rep- resent a form of aldosterone-producing micro-adenomas given the high-frequency of ion channel mutations [4, 5]. Similar to APN, a gradient of CYP11B2 reactivity from the external to internal fronts of the cellular proliferation occurs in APM [16].
A
3mm
CYP11B2
B
3mm
CYP11B2
Multifocal APN and/or APM This category refers to the occurrence of synchronous multifocal APN and/or APM in an adrenal gland (Fig. 15).
Aldosterone-producing diffuse hyperplasia (APDH) The HISTALDO classification defines APDH as a relatively broad and uninterrupted linear strip of zona glomerulosa cells with more than 50% of these cells showing CYP11B2 reactivity [16] (Fig. 15). This is the most common cause of bilateral idi- opathic primary aldosteronism that often requires lifelong anti- mineralocorticoid therapy [4, 5, 99]. The so-called “paradoxical zona glomerulosa layer hyperplasia,” which is typically seen in the non-lesional adrenal cortex adjacent to APAs and APNs, should not be mistaken for diffuse hyperplasia. Unlike the dif- fuse hyperplasia, the paradoxical hyperplasia is negative for CYP11B2 [4, 5]. The latter finding supports the non-functional status of the paradoxical zona glomerulosa layer hyperplasia.
Based on the HISTALDO classification, the identifica- tion of a solitary APA or APN refers to a classic histology whereas adrenals with APDH, multifocal APN and/or APM are considered to have non-classic histology [16]. This dis- tinction is of clinical significance since biochemical disease recurrence (due to bilateral disease) occurred in around 42% of patients with non-classic histology findings, compared to less than 5% in patients with classic histology [16].
Question 6: What are the Pathological Correlates of Adrenal Cortical Adenomas in the 2022 WHO Classification?
Adrenal cortical adenoma is a neoplasm of adrenocortical cell derivation that lacks morphologic features of malig- nancy. Adrenal cortical adenomas are characterized by het- erogeneity of pathological and clinical presentations; thus, their characteristics are influenced by the different pathoge- netic and functional scenarios, as well as histopathological variants. Adrenal cortical adenomas may be hormonally inac- tive or synthesize/secrete steroid hormones with subclinical or overt clinical manifestations. Cortisol and aldosterone secreting-adrenal cortical adenomas are the most frequent functional correlates of adrenal cortical neoplasms, although some patients may have concurrent primary aldosteronism and Cushing syndrome [4, 5, 108].
Grossly, most adrenal cortical adenomas are homogenous and well-delineated cortical neoplasms that are enriched in lipid-rich adrenal cortical cells resulting in a yellow color (Fig. 13). Oncocytic adrenal cortical adenomas have a char- acteristic Mahogany brown appearance, while “black adeno- mas” are composed of tumor cells with lipofuscin pigment
deposition [1]. Aldosterone-producing adrenal cortical ade- nomas (especially those harboring KCNJ5 mutations) typi- cally have a canary (golden) yellow appearance [1]. Most non-functional adrenal cortical adenomas have no distinct gross appearance. Non-tumorous cortical atrophy is a char- acteristic gross and microscopic feature of cortisol-secret- ing adrenal cortical adenomas (Fig. 16). Adrenal cortical adenomas are often solitary nodules; however, multifocal and/or bilateral manifestations can occur. Sporadic nodu- lar adrenal cortical disease (sub-centimeter non-functional benign adrenal cortical nodular proliferation) [1] is indis- tinguishable from functional adrenal cortical adenomas that measure <1.0 cm. The large tumor size and weight (>5 cm and > 100 g) as well as irregular border and heterogenous cut surface (e.g., necrosis, hemorrhage, fibrosis or gelatinous appearance) should alert the pathologist to the possibility of malignancy; therefore, extensive sampling or complete submission of the tumor is encouraged [1].
Histologically, adrenal cortical adenomas are composed of lipid-rich clear cells in a variable mixture with eosino- philic/compact cells. Clear-cut malignancy-related features such as vascular invasion, local invasion into adjacent structures, tumor necrosis unrelated to a former manipula- tion, atypical mitotic figures (even a single one), increased mitotic activity (>5 mitoses per 10 mm2) and a marked loss of reticulin framework (unrelated to an underlying degeneration or hemorrhage) are not seen in adrenal corti- cal adenomas. However, some other features included in multiparameter diagnostic scoring schemes may be present, thus posing problems in the differential diagnosis with adre- nal cortical carcinoma. Random nuclear atypia (correspond- ing to renal cell carcinoma Fuhrman/ISUP grade 3 or 4) may be focally identified. However, endocrine atypia should not be mistaken for nuclear atypia. Infarct-type necrosis may be detected as a result of involutional changes and should by no means be considered suggestive for malig- nancy, alone. If carefully searched, myelolipomatous areas are often detected in these cases [109] (Fig. 17). The term “oncocytoma” is no longer a recommended terminology for oncocytic adrenal cortical neoplasms. Irrespective of their biological behavior, oncocytic adrenal cortical neo- plasms are usually associated with diffuse growth pattern and presence of macronucleoli. Since these features are not indicative of malignancy in oncocytic cortical neoplasms, a diagnosis of malignancy cannot be rendered based on the Weiss scoring system, which incorporates these parameters. However, oncocytic adrenal cortical neoplasms are assessed using other diagnostic algorithms which are detailed in the next question.
Adrenal cortical origin should always be confirmed in all non-functional adrenal lesions and in adrenal neoplasms
1.951 mm
600um
with predominant oncocytic features (even in an otherwise morphologically benign lesion) to prevent clinically rel- evant diagnostic pitfalls, the erroneous misinterpretation with pheochromocytoma being the most common [110] (Fig. 18). When an adrenal cortical neoplasm shows a predominant myxoid change, the risk of underestimating malignancy has been well-documented [111]. However, myxoid change does not indicate malignancy, but the behavior of myxoid adrenal cortical neoplasms cannot be predicted with standard Weiss scoring systems as myxoid adrenal cortical tumors with a Weiss score of 1 have been associated with fatal disease [1].
A
B
C
Non-functioning adrenal cortical adenomas do not show characteristics histologic features, except for their relatively larger size as compared to functional adrenal cortical adeno- mas. Cortisol-secreting adrenal cortical adenomas are the most frequent cause of ACTH-independent Cushing syn- drome [15]. Clinical features of cortisol excess are extremely heterogeneous and include central obesity, rounded facies, hirsutism, poor wound healing, skin striae, weight gain, proximal muscle weakness, hypertension, hyperglycemia, osteoporosis, and susceptibility to infections [15]. How- ever, the clinical features may be subtle and pre-operative
A
B
C
D
dynamic endocrine work-up may be indeterminate or even not being performed. As a consequence, a subset of adrenal cortical adenomas with mild autonomous cortisol secretion (also known as subclinical Cushing syndrome) may simulate a non-functional adrenal cortical adenoma [5, 15]. Subsets of pigmented “black” adrenal cortical adenomas can show mild autonomous cortisol secretion [1]. In the absence of exogenous cortisol intake, the presence of adrenal cortical atrophy in the non-tumorous adrenal cortex is a hallmark of adrenal Cushing syndrome due to an autonomous cortisol- secreting adrenal cortical neoplasm [1, 5, 15, 112]. Reduced adrenal cortical thickness in association with significantly reduced to absent zona reticularis layer is a diagnostic feature of adrenal cortical atrophy [1, 5, 15] (Fig. 16). In patients with mild autonomous cortisol secretion, an inter- mittent absence of zona reticularis can be the first sign of cortical atrophy. Therefore, pathologists should carefully assess the non-tumorous adrenal cortex [112].
The former question focused on the morphological spec- trum of CYP11B2-positive clonal and hyperplastic adrenal cortical proliferations leading to primary aldosteronism.
Aldosterone producing cortical lesions can be unifocal or multifocal, and may be bilateral [1, 4, 5]. More importantly, not all grossly or radiologically identified adrenal cortical lesions can be the source of aldosterone excess [5, 113]. It is also not uncommon to have microscopic clonal nodular proliferations that cannot be identified on imaging stud- ies [16, 107]. For this reason, the new WHO classification endorses the use CYP11B2 immunohistochemistry in the workup of all adrenalectomy specimens from patients with primary aldosteronism to identify functional sites of aldos- terone secretion for the appropriate distinction of bilateral from unilateral aldosterone secreting lesions and predicting possible biochemical recurrence [114]. It is also important to recognize that APAs and APNs have distinct cytomor- phological features that are reflected in their genotype- phenotype correlations [1, 4, 5]. For instance, KCNJ5- mutant APAs and APNs are enriched in zona fasciculata- like clear cells whereas KCNJ5 wild-type tumors have been enriched in lipid-poor cells similar to zona reticularis [4, 5] (Fig. 19). In cases associated with primary aldosteronism treated with spironolactone, the drug may form eosinophilic
8.004 mm
concentrically laminated electron dense inclusions, both in the tumor (Fig. 20) and the adjacent adrenal cortex (particu- larly in the zona glomerulosa), the so-called spironolactone bodies [1, 99]. Spironolactone bodies can be highlighted using Luxol-Fast blue histochemistry [99] (Fig. 20). Interest- ingly, similar inclusions are not detected in patients treated with other aldosterone antagonists, such as eplerenone [115].
Sex steroid-producing adrenal cortical adenomas are exceptional, especially in the adult population, and the pres- ence of virilization or feminization should always increase the suspicion of malignancy [4, 116].
Question 7: Have the Pathologic Criteria for Adult Adrenal Cortical Carcinomas Changed in the 2022 WHO Classification?
Adrenal cortical carcinomas (ACCs) in adults may be clini- cally apparent due to the functional status with hormone secretion in approximately half or an abdominal mass, although approximately 10-15% may be incidentally detected [1, 117, 118]. Functional ACCs are usually gluco- corticoid producing or produce both glucocorticoids and sex steroids [1]. An adrenal cortical neoplasm associated with virilization or feminization is highly worrisome for malig- nancy [1, 119], while aldosterone producing adrenal cortical carcinomas are rare [101, 102].
The classic pathologic criteria for the diagnosis of adult ACCs have not changed (Figs. 21, 22, 23, 24, and 25); how- ever, the 2022 WHO classification underscores the diagnos- tic and prognostic impact of angioinvasion (vascular inva- sion) in these tumors [120]. Vascular invasion is assessed at the intersection of the tumor and adrenal capsule or beyond the adrenal capsule [1, 120, 121] (Fig. 21). While gross or clinically detected large vessel invasion is a finding of advanced ACCs [121] (Fig. 22), microscopic angioinvasion is defined when tumor cells invade through a vessel wall and form a thrombus/fibrin-tumor complex or intravascu- lar tumor cells admixed with platelet thrombus/fibrin [120, 121] (Fig. 21). While the new classification emphasizes the diagnostic and predictive role of ancillary biomark- ers in ACCs (see Questions 9 and 10), the role of CD61
*
A
B
A
O
B
.
*
.
+
immunohistochemistry in the detection of platelets at sites of angioinvasion is also noted in the new WHO classification.
ACCs are subtyped based on their characteristic cyto- morphological features to include conventional [1], onco- cytic [122], myxoid [111, 123, 124], and sarcomatoid ACCs [1, 125] (Fig. 26). Oncocytic ACCs are composed of oncocytic tumor cells that account for more than 90% of the tumor [121, 122]. Myxoid ACCs are characterized by prominent extracellular mucin deposition [111, 123, 124]. Some Weiss parameters (e.g., lack of diffuse growth, nuclear atypia or lymphatic invasion) may be difficult to assess in myxoid adrenal cortical neoplasms. Sarcomatoid carcinomas resemble sarcomatoid carcinomas of various organs and often show adrenal cortical differentiation
[126, 127]. Sarcomatoid ACCs that are unassociated with other subtypes of ACCs need to be distinguished from sarcomas.
The classic criteria of Weiss and colleagues described in 1984 and modified (also known as modified Weiss system) in 1989 continue to be used for the classification of con- ventional adrenal cortical neoplasms in adults [128, 129] (Tables 1 and 2). For conventional ACCs in adults, 3 of the 9 histologic parameters in the Weiss criteria need to be present for a diagnosis of malignancy (Table 1). The new WHO classification also expands the use of other multipa- rameter diagnostic algorithms to assist the workup of adre- nal cortical neoplasms in adults. These include (a) reticulin algorithm which can be used for conventional, oncocytic and myxoid adrenal cortical neoplasms [120, 121, 130, 131], (b) Lin-Weiss-Bisceglia system for oncocytic adrenal corti- cal neoplasms [122], and (c) Helsinki scoring system which can be used for conventional, oncocytic and myxoid adrenal cortical neoplasms [121, 132, 133].
The reticulin algorithm (Table 3) has gained popular- ity in the workup of adrenal cortical neoplasms given its reproducibility [1, 120, 121, 130]. A diagnosis of ACC is rendered when an altered reticulin network (see Question 10) (Fig. 27), as demonstrated by the Gordon Sweet silver histo- chemical stain, is seen in association with one of the follow- ing parameters: (i) the presence of mitotic rate > 5 mitoses per 10 mm2 (50 high-power fields), (ii) tumor necrosis, or (iii) vascular invasion (angioinvasion) [120, 130, 131, 134].
The Lin-Weiss-Bisceglia system (Table 4) has been developed to evaluate oncocytic adrenal cortical neoplasms [122, 128, 135]. Of note, it is important that oncocytic
A
B
C
| Parameter | Score |
|---|---|
| High Fuhrman nuclear grade (III or IV) | 1 |
| Mitotic count> 5 per 50 high-power fields (10mm2) | 1 |
| Atypical mitosis | 1 |
| Necrosis | 1 |
| Diffuse architecture > 30% of tumor volume | 1 |
| Clear cells ≤25% of the tumor volume | 1 |
| Capsular invasion | 1 |
| Venous invasion | 1 |
| Sinusoidal (lymphatic) invasion | 1 |
| Total score | 9 |
| A score of≥ 3 indicates a diagnosis of adrenal cortical carcinoma |
| Parameter | Score |
|---|---|
| Mitotic count> 5 per 50 high-power fields (10 mm2) | 2 |
| Clear cells in ≤25% | 2 |
| Atypical mitosis | 1 |
| Necrosis | 1 |
| Capsular invasion | 1 |
| Total score | 7 |
A score of≥ 3 indicates a diagnosis of adrenal cortical carcinoma
adrenal cortical neoplasms are extensively sampled to be certain that they do fit into the category of pure oncocytic tumors to use this classification system. Greater than 90% of the tumor must be oncocytic for it to be regarded as a pure oncocytic adrenal cortical neoplasm. If it is not a pure onco- cytic adrenal cortical neoplasm, then the criteria applied to conventional adrenal cortical carcinomas should be used. The “Lin-Weiss-Bisceglia” system is comprised of major (high mitotic rate, atypical mitosis, or vascular invasion) and minor criteria (large size and huge weight, necrosis, capsu- lar invasion, or sinusoidal invasion) [122]. The diagnosis of malignancy requires the presence of at least one major criteria, whereas the presence of at least one minor criterion would indicate a tumor of uncertain malignant potential, and no major or minor criteria would be an oncocytic adrenal cortical adenoma.
The Helsinki score (Table 5) integrated the numeric value of Ki67 labeling index (using an automated image analysis nuclear algorithm) by adding scores assigned to increased mitotic rate (score 3 for mitotic rate greater than 5 mitoses per 10 mm2) and tumor necrosis (score 5). A Hel- sinki score> 8.5 is diagnostic of ACC, and a score of> 17 has been suggested to be helpful in predicting metastasis in adrenal cortical tumors [132, 133].
A variety of immunohistochemical and molecular bio- markers have been evaluated diagnostically and prog- nostically in ACCs [18, 120, 127, 136-138]. While IGF2 immunohistochemistry (Fig. 28) is a useful translational diagnostic immunohistochemical biomarker of ACC [120], the role of Ki67 (Fig. 29) as a diagnostic and prognostic biomarker [120, 139-142] has been expanded in this new
Table 3 Reticulin algorithm
Criteria
Altered reticulin framework in association with one of the following features indicates malignancy:
-Mitotic count> 5 per 50 high-power fields (10 mm2)
-Tumor necrosis
-Vascular invasion (angioinvasion)
A
EN
B
C
| Major criteria | Minor criteria |
|---|---|
| Mitoses > 5 per 50 high-power fields (10 mm2) | Large size (>10 cm and/ or>200 g) |
| Atypical mitosis | Necrosis |
| Venous invasion | Capsular invasion |
| Sinusoidal invasion |
Oncocytic adrenal cortical carcinoma: at least one major criterion Oncocytic adrenal cortical neoplasm of uncertain malignant poten- tial: at least one minor criterion
Oncocytic adrenal cortical adenoma: absence of major and minor criteria
| Parameter | Score |
|---|---|
| Mitoses > 5 per 50 higher-power fields (10 mm2) | 3 |
| Necrosis | 5 |
| Ki67 proliferation index (%)* | Numeric value of the Ki67 index from the highest proliferative area |
| Score 0 to 8.5: adrenal cortical adenoma | |
| Score> 8.5: adrenal cortical carcinoma | |
| Score> 17: adverse prognosis |
*The original study used an automated image analysis for the assess- ment of the Ki67 proliferation index
classification. The details on the mitotic tumor grade, Ki67 labeling index, and other immunohistochemical and molecu- lar biomarkers are discussed in subsequent sections of this review.
Question 8: What are the Clinicopathological Correlates of Pediatric Adrenal Cortical Carcinomas in the 2022 WHO Classification?
Pediatric ACCs are uncommon adrenal cortical neoplasms, with an annual incidence of 0.2 to 0.3 cases per million population or 25 patients per year in the USA [143]. Com- pared to adult forms, pediatric ACCs show distinct clinical, molecular, and pathologic characteristics [139].
Ki67
In terms of epidemiologic correlates, pediatric ACC have two age peaks, one before the age of 5 years and a second in adolescents. While very rare, they have a 15-fold increased frequency in the southern part of Brazil, due to the occur- rence of a TP53 p.R337H founder mutation [144, 145]. In this age range, ACCs more frequently present with excess hormone secretion than in adults, with excess androgen secretion being the most frequent presentation in up to 80%
IGF2
60um
of patients, leading to signs of virilization in both boys and girls, with pubic hair growth, enlargement of penis or clitoris and hirsutism [146]. Less commonly, excess cortisol secre- tion leads to Cushing syndrome [147].
In contrast to adults, up to 80% of ACCs in children are linked to pathogenic germline TP53 variants as the most com- mon genetic abnormality, not only in geographic areas with increased incidence, but also elsewhere [148]. Indeed, ACC is a well-recognized entity in the context of Li-Fraumeni syndrome [127, 148-151]. Genomic instability caused by loss of p53 leads to loss of heterozygosity of 11p15 with resultant IGF2 overexpression, which may act as a driver for ACC development. Interestingly, the hereditary variant of 11p15 abnormalities, Beckwith-Wiedemann syndrome, may also present with pediatric ACCs, underlining the impor- tance of this pathogenetic pathway [151]. Additional somatic mutations in ATRX and CTNNB1 have been described, which may result in poor outcome [152].
The macroscopic features of pediatric ACC largely resemble those of adult ACCs, with large tumors showing signs of hemorrhage, necrosis, and gross tumor extension beyond the adrenal gland. This is in contrast to benign adre- nal cortical tumors which lack such signs. However, most adrenal cortical tumors are limited to the adrenal gland and thus gross appearance only infrequently contributes to tumor classification.
The histological characteristics of pediatric ACC are not different than their adult counterparts; however, the interpre- tation of histological findings and consequent classification are different (Table 6). Cytologically, they are composed of adrenal cortical cells with eosinophilic or clear cytoplasm, sometimes with oncocytic differentiation. Nuclear pleomor- phism may be pronounced, with prominent nucleoli and/
| Parameter | Score |
|---|---|
| Tumor weight>400 g | 1 |
| Tumor size> 10.5 cm | 1 |
| Extension into periadrenal soft tissue or adjacent organs | 1 |
| Invasion into vena cava | 1 |
| Vascular invasion | 1 |
| Capsular invasion | 1 |
| Presence of tumor necrosis | 1 |
| Mitoses > 15 per 20 high-power fields (4 mm2) | 1 |
| Presence of atypical mitosis | 1 |
| Total score | 9 |
| Malignant/poor outcome: score ≥ 4 poor clinical outcome | |
| Uncertain malignant potential: score 3 | |
| Benign behavior: score ≤ 2 |
or giant nuclei. Mitoses may be frequent. The presence of atypical mitoses is a very helpful criterion to establish a diagnosis of ACC, although these are frequently not pre- sent. Architecturally, tumors are characterized by nodular, trabecular or diffuse growth, with areas of necrosis and sometimes signs of vascular invasion (angioinvasion), lym- phatic invasion, or adrenal capsule invasion. Unfortunately, the classification of pediatric adrenal cortical tumors is fraught with difficulty, and classification on the basis of the Weiss criteria, used for adult counterparts, leads to over- diagnosis of tumors with benign clinical behavior as ACC in children [153]. Thus, the currently preferred criteria are those described by Wieneke et al. in 2003 [154] (Table 6). However, additional studies are required to validate the role of various other multiparameter systems. Recently, Ki67 (MIB1) immunohistochemistry (see Question 9) has been proposed as an ancillary biomarker in the distinction of pedi- atric adrenal cortical adenomas from ACC as well as in the prediction of tumor behavior, with a labeling index less than 10% associated with benign disease and a labeling index of greater than 15% related to higher risk of malignancy or poor outcome [139, 155].
Although the AJCC TNM staging system is widely used in ACCs, a clinical staging scheme has been proposed by the Children’s Oncology Group (COG), according to tumor weight, completeness of resection and presence of metastases [156-158] (Table 7). When present, the brain, liver, lungs, and bone are the organs most frequently affected by metastases [159]. In addition to the role of Ki67 immunohistochemistry, meta-analyses have also confirmed the prognostic significance of the following parameters: age, stage, tumor weight> 200 g, extra-adrenal extension, incomplete resection, metastatic dis- ease, and cortisol secretion [152, 155, 157].
Question 9: What is the Role of Mitotic Tumor Grade and the Ki67 Index in Adult and Pediatric Adrenal Cortical Carcinomas?
The 2022 WHO classification emphasizes the importance of an accurate assessment of tumor proliferation rate using both the mitotic count (as per 10 mm2) (Fig. 24) and Ki67 labeling index (Fig. 29) in the dynamic risk stratification of tumors [1, 121]. In adrenal cortical pathology, increased mitotic activity is defined when an adrenal cortical tumor shows a mitotic count that exceeds 5 mitoses per 10 mm2 (50 high-power fields) [129, 132, 160-162]. This cutoff has been widely applied in all traditional multiparametric diagnostic schemes in adults [129, 132, 160-162]; however, a mitotic count that exceeds 15 mitoses per 4 mm2 (20 high-power fields) has been used in pediatric manifestations given their distinct features [154].
| Table 7 The Children's | Stage I: Tumor completely excised with negative margins, tumor weight <200 g, no metastases Stage II: Tumor completely excised with negative margins, tumor weight> 200 g, no metastases Stage III: Microscopic or gross incomplete resection or inoperable tumor Stage IV: Hematogenous metastasis at clinical presentation |
| Oncology Group (COG) staging system for pediatric adrenal cortical tumors |
The 2022 WHO classification of adrenal cortical carci- nomas adopts the mitotic tumor grade that was originally introduced by Weiss et al. [128]. This grading system uses the cut-off of 20 mitoses per 10 mm2 to distinguish low- and high-grade carcinomas. Low-grade adrenal cortical carci- nomas have a mitotic activity ≤ 20 mitoses per 10 mm2, whereas high-grade adrenal cortical carcinomas show > 20 mitoses per 10 mm2 [120, 128, 163]. The prognostic value of this approach has been validated in cohorts from adult tumors [120, 121, 163]; however, it remains to be validated in pediatric adrenal cortical carcinomas [164]. Two inde- pendent series from Duregon et al. [142] and Mete et al. [120] also showed that a cut-off of 10 mitoses per 10 mm2 shows a better performance; however, further validation of the optimum cut-off points is encouraged.
Counting mitoses especially in the setting of low- grade adrenal cortical carcinomas may be facilitated using phosphoHistone-H3 immunohistochemistry [1, 18, 142] (Fig. 24). The original study on adrenal cortical carcinoma employed a methodology that is based on mitotic count from 10 high-power fields on 5 different sections (50 high- power fields in toto) with high-mitotic density; however, it is also acceptable to count mitoses in 10 mm2 (50 high-power fields) from hot spots in multiple individual slides with high mitotic density.
In terms of the Ki67 proliferation index, most adrenal cor- tical carcinomas show a labeling index that typically exceeds 5% [4, 18, 120, 139, 155, 165-168] (Fig. 29). Clinical series from adult and pediatric adrenal cortical carcinomas under- scored the prognostic role of Ki67 in both adult and pediatric adrenal tumors [120, 139, 141, 142, 155]. While some large clinical series introduced a three-tiered Ki67 cutoffs (<10%, 10-19%, ≥ 20%) for prognostication of adrenal cortical car- cinomas [141], others have applied different prognostic cut- offs (<20%, 20-50%,>50%)[142]. In addition, two recently published independent cohorts of pediatric adrenal cortical carcinomas underscored the cutoff of 15% as of prognostic significance [139, 155].
The recently validated S-GRAS (Stage, Grade based on the Ki67 labeling index, Resection status and Symptoms) scoring scheme has shown a better prognostic significance compared to the tumor stage and Ki67 proliferation index in patients with adrenal cortical carcinomas [169]. The Ki67 proliferation index is a component of the Helsinki scoring system that uses the proliferation index as a continuous numeric value [132]. Ki67-based tumor grading has not been
endorsed in the 2022 WHO classification of adrenal cortical carcinomas, since the proliferation indices are continuous variables rather than being static thresholds in tumor biol- ogy. However, the WHO classification of adrenal cortical carcinoma classification recommends diagnosticians specify the numeric value for mitotic count (as per 10mm2) and Ki67 labeling index in all adrenal cortical carcinomas.
Another point to remember is adrenal cortical carcinomas frequently show proliferative heterogeneity [1, 121]; thus, the identification of hot spots is an important step to ensure accurate assessment of the mitotic tumor grade and Ki67 proliferation index in these tumors. Given the impact of the Ki67 labeling index in the dynamic risk stratification that also rationalizes the of adjuvant mitotane therapy [1, 118], the new WHO classification does not suggest eye-balling for reporting of the Ki67 proliferation index. Similar to all neu- roendocrine neoplasms, the assessment of Ki67 proliferation index is done with either manual count or automated image analysis nuclear algorithms [1, 121, 140, 170] (Fig. 30). Pathologists should document the methodology used in their assessment of Ki67 and mitotic count [171].
Question 10: Which Ancillary Tools should Pathologists Consider Utilizing in the Workup of Benign and Malignant Adrenal Cortical Proliferations?
The 2022 WHO classification emphasizes the role of ancillary tools in the workup of adrenal cortical proliferations to ensure accurate tumor classification. Several ancillary tools may be used by pathologists in the diagnostic assessment of adrenal cortical lesions. Molecular studies may be utilized as diagnostic and/or prognostic ancillary tools in select clinical settings [1, 4, 127, 172-175]; however, molecular studies do not form the basis of the standard of clinical practice. Therefore, the modern endocrine pathology practice relies on the application of immu- nohistochemical biomarkers and/or histochemical stains (e.g., Gordon Sweet Silver in the workup of malignancy, Luxol Fast Blue in the distinction of spironolactone bodies) that are inter- preted in association with morphological and clinical findings [1, 18, 120, 130]. Therefore, diagnosticians should be aware of the various situations that may require the application of specific biomarker studies to meet clinical practice.
In adrenal cortical proliferations, ancillary tools are typi- cally used to address specific needs such as the (i) distinction
Layer Attributes
¢
0
Algorithm
Nuclear v9
A
Date
2021/10/04
StartTime
01:42:08 PM
EndTime
01:42:12 PM
Status
0
StatusDescription
Percent Positive Nuck 30.1084
Intensity Score
2
(3+] Percent Nuclei
15.2148
(2+] Percent Nuclei
6 34283
[1+] Percent Nuclei
8.55078
10+] Percent Nuclei
69.8916
Average Positive Inter 163.768
Average Negative Inte 231.2
Average Nuclear RGB 167.274
Average Nuclear Size 286.984
Average Nuclear Size 71.66
Area of Analysis [Pixel: 2912346.
Area of Analysis (mm“: 0.7272130583111399
*** Algorithen Inputs *** *** Algorithm Inputs **
Version
9.1
View Width
1000
8
View Height
1000
Overlap Size
100
Image Zoom
1
Classifier
None
Class List
Classifier Neighborhoo 0
Pacel Size (um)
0.4997
Averaging Radius (um) 1.
200um
| (3+] Nuclei | 379 |
|---|---|
| [2+] Nuclei | 158 |
| [1+] Nuclei | 213 |
| [0+] Nuclei | 1741 |
| Total Nuclei | 2491 |
Fig. 30 Assessment of Ki67 labeling index in adrenal cortical carci- nomas. The new WHO classification does not suggest eye-balling for reporting of the Ki67 proliferation index. Similar to all neuroendo- crine neoplasms, the assessment of Ki67 proliferation index is done with either manual count or automated image analysis nuclear algo-
of the adrenal cortical origin, (ii) confirmation of functional adrenal cortical lesions especially in the context of primary aldosteronism, (iii) distinction of malignancy, (iv) risk strati- fication in ACC, (v) providing theranostic information in ACC, and (vi) rationalization of the need for genetic screen- ing for underlying germline pathogenic variants [1, 18, 120].
The confirmation of the adrenal cortical origin is a criti- cal task especially when dealing with non-functional adre- nal lesions which may be mistaken for a primary adrenal cortical neoplasm. Therefore, the new WHO classification emphasizes the confirmation of the adrenal cortical ori- gin as an important step in the diagnostic workup of these tumors. From that perspective, the use of SF1 immunohis- tochemistry (Fig. 31) is encouraged since it has been shown to be the most reliable and specific biomarker of adrenal cortical origin [18]. Other non-specific biomarkers such as Melan-A, synaptophysin, alpha-inhibin and calretinin may only be used in a panel approach; however, it is important to recognize their limitations [18]. Similar to synaptophysin, alpha-inhibin cannot be used in the distinction of an adrenal cortical lesion from a pheochromocytoma (adrenal para- ganglioma) since paraganglioma/pheochromocytoma with
rithm. Pathologists should document the methodology used in their assessment of Ki67. This photomicrograph illustrates an automated image analysis nuclear algorithm in the assessment of Ki67 prolifera- tion index
a pseudohypoxia-driven pathogenesis often show reactivity for alpha-inhibin [176].
SF1
In the past, ultrastructure examination has helped in the distinction of aldosterone-producing adrenal cortical pro- liferations from other steroidogenic adrenal cortical lesions by assessing characteristics of the mitochondrial cristae. This distinction was based on aldosterone-producing cells typically showing plate-like cristae, whereas tubulovesicu- lar cristae featured cortisol-producing adrenal cortical cells [112]. However, the modern endocrine pathology practice applies functional immunohistochemistry in the distinction of certain functional states of adrenal cortical proliferations [18]. Several antibodies against steroidogenic enzymes have shown value in the workup of adrenal cortical pro- liferations. These include (but not limited to) HSD3B1 (3ß-hydroxysteroid dehydrogenase type 1), HSD3B2 (36-hydroxysteroid dehydrogenase type 2), CYP11B1 (cytochrome P450 family 11 subfamily B member 1), CYP11B2 (cytochrome P450 family 11 subfamily B mem- ber 2, also known as aldosterone synthetase), and CYP21A2 (cytochrome P450 family 21 subfamily A member 2) [1, 18]. Among these, the most popular ones have been CYP11B1 and CYP11B2. While CYP11B1 is considered as a func- tional biomarker of the zona fasciculata-like cells, CYP11B2 (aldosterone synthase) has gained popularity due to its important role in the distinction of aldosterone-producing cortical lesions which may be difficult on H&E-stained sec- tions [16, 18, 120]. As a consequence, the new WHO classi- fication endorses the use of CYP11B2 immunohistochemis- try, which forms the basis of HISTALDO classification, that provides clinicopathologically relevant diagnostic categories in the workup of primary aldosteronism [16].
Although SF1 is the most reliable biomarker in the con- firmation of adrenal cortical origin, this biomarker is also expressed in gonadotroph tumors (pituitary neuroendocrine tumors with gonadotroph cell differentiation) as well as in a subset of steroidogenic gonadal neoplasms (e.g., steroid cell tumor, Leydig cell tumor) [177]. These pitfalls should be kept in mind when assessing metastatic tumors with SF1 expression or when assessing adrenal rest-related manifes- tations including adrenal cortical choristomas in anatomic sites beyond the developmental pathway (e.g., pituitary corticotroph tumor with adrenal cortical choristomas) [50, 51]. When the distinction of an adrenal cortical origin from a steroidogenic gonadal tumor is required, adrenal cortex- specific steroidogenic enzymes may also provide additional value [1]. For instance, the application of CYP11B1 and CYP21A2 has shown promise in the distinction of TARTs (testicular adrenal rest tumors) from Leydig cell tumors [58]. Although most laboratories currently do not have access to the full spectrum of functional immunohistochemistry tools, it is important to know that there are additional biomarkers (e.g., abundance of DLK1 and lack of INSL3 expression) that may be used in the distinction of TARTs from Leydig cell tumors [58].
Several biomarkers can be used to support the diagnosis of malignancy in the background of appropriate morphologi- cal features. As discussed in the former question, ACCs typi- cally exceed a Ki67 labeling index of 5% [4, 18, 120, 139, 155, 165-168], and the value of Ki67 also matters in terms of tumor prognostication. An abnormal p53 expression (overexpression or global loss) (Fig. 32) and/or nuclear beta- catenin expression (Fig. 33) may be identified in a subset of ACCs, which are typically enriched in high-grade carcino- mas that are reflected in poor-prognostic molecular clusters [127]. However, such tumors are easily diagnosed based on conventional morphological features, whereas the distinc- tion of a low-grade ACC with no angioinvasion or extra- adrenal tumor spread may remain a diagnostic challenge [120]. Therefore, the confirmation of increased prolifera- tion (Ki67 labeling index and phosphoHistone-H3 assisted mitotic count) may assist the diagnosis of malignancy in association with other ancillary tools. Evidence suggests that irrespective of the tumor grade or cytomorphological features (e.g., oncocytic versus conventional) (Figs. 28 and 34), a juxtanuclear granular IGF2 expression (optimized at 1/3000-1/6000 dilutions) has been shown to be the best diagnostic ancillary tool in ACCs [120]. This finding occurs in around 80% of ACCs in adult series [28877067] and is thought to reflect IGF2 overexpression-related impaired translation and processing of the IGF2 molecule in the Golgi apparatus [178].
While access of IGF2 immunohistochemistry is not widely available, an additional practical tool is the dem- onstration of reticulin alterations using the Gordon-Sweet Silver histochemistry (Fig. 27). As discussed before, an altered reticulin framework forms the basis of the reticulin
P53
B-catenin
B-catenin
algorithm which combines altered reticulin framework with one of the followings: (i) necrosis, (ii) vascular inva- sion (angioinvasion), and (iii) increased mitotic activity (>5 per 10 mm2) [120, 121, 130, 131]. However, diagnosticians should recognize potential pitfalls with respect to the assess- ment of reticulin histochemistry. Most ACCs tend to show a quantitative alteration (loss of reticulin framework) but may have associated qualitative alterations (mesh-like peri- cellular pattern) [120]. The qualitative alterations alone do
not stand out as a concerning feature of carcinoma since focal/variable qualitative reticulin alterations may occur in adrenal cortical adenomas which are associated with a preserved reticulin framework [120]. In addition, areas of degeneration including sites of hemorrhage or biopsy sites in benign cortical proliferations can show disrupted reticulin [1].Therefore, it is important to match reticulin alterations with morphological findings.
Global loss of DAXX and/or ATRX expression (Fig. 35) may also be identified in ACCs, and this has shown to have prognostic value [18, 120, 136]. The application of MMR proteins (MLH1, MSH2, MSH6 and PMS2) has gained pop- ularity not only for the purpose of screening for an extra- colonic manifestation of Lynch syndrome [18, 179, 180] (Fig. 36), but also to provide additional guidance on the use of immunotherapy trials [4, 181]. Similarly, the PDL1/ PD1 expression status of ACCs has been an area of inter- est. There are also other theranostic biomarkers including CYP2B6 polymorphism that have shown variable prom- ise with respect to the prediction of mitotane response in patients with ACCs [18, 182, 183]; however, these biomark- ers are not widely used as the standard of practice in most diagnostic laboratories.
Similar to the role of MMR immunohistochemistry in Lynch syndrome (Fig. 36), a number of biomarkers may be used to facilitate the screening of genetic susceptibility in the setting of appropriate clinical and morphological con- text [1]. These include (a) nuclear beta-catenin and loss of APC expression in FAP-related adrenal cortical neoplasia), (b) loss of SDHB expression in adrenal cortical neoplasia that occur in the setting of SDH-deficient paraganglioma syndrome, (c) abnormal p53 expression (Li-Fraumeni syn- drome), (d) loss of menin expression (MEN1-related adrenal cortical neoplasia), and (e) loss of p27 expression (MEN4- related adrenal cortical neoplasia) [1, 4, 184].
IGF2
ATRX
PMS2
MLH1
Question 11: What are the Molecular Correlates of Adrenal Cortical Proliferations in the 2022 WHO Classification? Are There Any Diagnostic or Prognostic Molecular Studies in the Workup of Adrenal Cortical Carcinoma?
The molecular background of adrenal cortical neoplasia is multifaceted and heterogenous. In aldosterone- and cortisol- producing adrenal cortical adenomas, the underlying genetic aberrancies are often missense mutations that often hijack the physiological pathways leading to cell proliferation and hormone secretion-which is governed by an amplified cell membrane depolarization in aldosterone-secreting adenomas and increased protein kinase A (PKA) pathway signaling in cortisol-producing adenomas [4, 5]. Adrenal cortical carci- noma often displays multiple gross chromosomal alterations as well as mutations and deletions of genes regulating clas- sical cancer-associated signaling networks, such as the Wnt and P53 pathways [4]. As it is expected that molecular analy- ses will become an integrated part of the work-up of these
lesions in the future, an understanding of the background genetics propelling these tumors will be necessary in order to provide an optimal diagnostic and prognostic assessment, as well as to identify possible therapeutic options for non- responding cases. In this question, we focus on common genetic aberrancies underlying the development of primary hyperaldosteronism, cortisol-producing adrenal cortical adenomas as well as ACCs. As cortisol-producing adrenal cortical nodular disease patients often carry germline vari- ants in susceptibility genes, the genetics of these lesions are separately discussed in the next question.
Molecular Correlates of Primary Aldosteronism
The advent of next-generation sequencing has led to ground- breaking molecular findings in aldosterone-producing adre- nal cortical lesions and has helped establish this tumor entity as a disease of defective ion channels. In the absence of extracellular angiotensin II, the normal zona glomerulosa cell is in a resting state facilitated by G-protein activated inward rectifier potassium channel 4 (GIRK4) encoded by the KCNJ5 gene, a membrane-bound K+ channel that allows K+ to exit the cell and ensure a membrane hyperpolariza- tion. The build-up of this membrane potential will mediate entry into the G0 phase of the cell cycle, and no CYP11B2 (aldosterone synthase) enzyme will be produced. Upon physiological response to angiotensin II binding its recep- tor, the GIKR4/KCNJ5 channels close, and depolarization is mediated through the accumulation of intracellular K+. This will initiate an intracellular signaling cascade, leading to cell cycle activation and aldosterone production [4]. In aldosterone-producing adrenal cortical adenomas (irrespec- tive of the size of the cortical proliferation), this process is mimicked through somatic mutations in genes encoding several different ion channel proteins. These mutations will cause constitutive membrane depolarization, even in the absence of extracellular angiotensin II, leading to augmented cell proliferation (Fig. 37). Mutations in KCNJ5 [185, 186], CACNAID [187-189], and CACNA1H [187, 190, 191] will cause depolarization through the influx of Na+ (KCNJ5) or Ca2+(CACNA genes), while mutations in ATP1A1 [185, 188, 192] and ATP2B3 [185, 192] will impede the normal function of these ion channels, i.e., to leak Na+ and Ca2+ respectively to the extracellular compartment-thus lead- ing to membrane depolarization (Fig. 37). Intriguingly, sub- sets of patients with autosomal dominant forms of familial hyperaldosteronism have also been linked to pathogenic ger- mline variants in KCNJ5, CACNA1D, CACNA1H, as well as the CLCN2 chloride channel gene [4].
Somatic ion channel mutations were initially reported in approximately half of sporadic aldosterone-producing adrenal cortical adenomas, of which somatic KCNJ5 muta- tions alone account for 40% of cases-notably with an
Aldosterone producing adrenal cortical adenoma
Cortisol producing adrenal cortical adenoma
Mutated KCNJ5
Mutated ATP1A1
Mutated ATP2B3
Mutated CACNA1D
Mutated CACNA1H
MC2R
Adenylyl cyclase (AC)
+
-
-
+
+
+
as +
PDE
CAMP
Increased intracellular Na+
Increased intracellular Ca2+
PKA-CX PKA-C
Depolarization
PKA-RX PKA-R
PKA-CX PKA-C + ++
CAMP
PKA-RXPKA-R
Proliferation
Proliferation
Aldosterone production
Cortisol production
overrepresentation in younger female patients with marked hormonal activity, with possible correlations also to the adrenal vein sampling lateralization index as well as the overall histology-notably zona fasciculata-like clear cells [193-195]. In contrast, KCNJ5 wild-type tumors are more frequent in males with a later age at presentation and recur- rently display smaller tumor sizes and not seldom a compact cell morphology [5]. Despite the early work suggesting ion channel mutations in approximately 50% of patients, the true proportion of patients with is probably much higher, probably between 90 and 96% as indicated by more recent work relying on positive CYP11B2 immunoreactivity as an inclusion criterion [187, 196, 197]. Moreover, muta- tions in ion channels are not only restricted to conventional aldosterone-producing adrenal cortical adenomas but are also found in other benign neoplastic proliferations referred to as aldosterone-producing nodules (multiple adenomas)
and micronodules (multiple microadenomas) [198, 199]. The very rare aldosterone-producing ACCs do not exhibit mutations in well-characterized ion channel genes, and additional molecular aberrancies is likely to drive the over- expression of CYP11B2 in these cases [101].
While ion channel mutations occur in the vast majority of benign, aldosterone-producing lesions, approximately 5% of sporadic aldosterone-producing adrenal cortical adenomas display mutually exclusive CTNNB1 mutations [200, 201]. This gene encodes beta-catenin, a Wnt signaling pathway effector, and activating CTNNB1 mutations allows this pro- tein to escape proteasome-mediated degradation and trans- locate to the nucleus, where it will associate to various tran- scription factors and initiate gene transcription. In adrenal cortical disease, CTNNB1 mutations are best-known to be recurrently observed in adrenal cortical carcinoma, as well as in non-functional adrenal cortical adenomas and adrenal
cortical adenomas with mild autonomous cortisol produc- tion (also known as subclinical Cushing syndrome) [127, 202-204]. Interestingly, while CTNNB1 mutations are rare, a general Wnt pathway activation seems to be a regular theme in aldosterone-producing adrenal cortical adenoma [205]. While the exact mechanisms coupling the Wnt pathway to aldosterone production is not known, there have been studies indicating a link between aberrant beta-catenin expression and up-regulation of angiotensin II receptors as well as the CYP11B2 enzyme [205].
Molecular Correlates of Cortisol-Producing Adrenal Cortical Adenomas
Just like aldosterone-producing adrenal cortical lesions hijack the physiological pathways of angiotensin II stimu- lation via mutations, cortisol-producing adenomas display genetic aberrancies in the ACTH response mediated protein kinase A (PKA) pathway. In the normal zona fasciculata, the cells respond to ACTH stimulation via the melanocortin 2 receptor (MC2R), thus activating a cascade in which cAMP is produced from ATP via the enzyme adenylyl cyclase. The cAMP molecules in turn will inhibit regulatory subunits of PKA, allowing the catalytic subunits to stimulate prolifera- tion and cortisol production (Fig. 37).
In cortisol-producing adenomas, mutations in PRKACA, PRKARIA, GNAS, and PRKACB are observed-and these aberrations will in different ways lead to over-activation of the PKA pathway [206-212].
Recent pan-genomic work regarding benign correlates of adrenal Cushing syndrome suggest that these entities segre- gate into three distinct clusters, including (a) PPNADs and cortisol-producing adrenal cortical adenomas coupled to an activated PKA pathway, (b) adrenal cortical adenomas with mild autonomous cortisol secretion associated to the activa- tion of the Wnt signaling pathway, and (c) ARMC5-driven primary bilateral macronodular adrenal cortical disease with a coupling to a specific ovarian gene expression signature [172].
Adrenal Cortical Carcinoma
Most ACCs arising in the adult population do so through an accumulation of somatic genetic aberrances. The pinpoint- ing of genes associated to the development of this disease is an effort that spans over several decades and include gene- specific studies as well as pan-genomic analyses. In compar- ison to adrenal cortical adenomas, ACCs commonly display mutually exclusive driver gene alterations associated to the Wnt and P53 pathways, as well as aberrant IGF2 signaling and complex gross chromosomal aberrations-all features those adrenal cortical adenomas regularly lack [4] (Fig. 38). Moreover, ACCs are characterized by a global hypometh- ylation pattern, as opposed to adenomas that display global hypermethylation.
Recurrent genetic events in ACCs include activating CTNNB1 mutations and deleterious ZNRF3 mutations (alter- natively homozygous ZNRF3 copy number loss), which will
Adrenal cortical adenoma
Adrenal cortical carcinoma
lon channel mutations (aldosterone producing tumors)
Aberrant IGF2 signalling
Wnt pathway/ beta-catenin activation
PKA pathway mutations (cortisol-secreting tumors)
Aberrant p53 signaling & inhibition of apopotosis
Low number of chromosomal events
Frequent chromosomal aberrations
Global hypermethylation
Me Me)
Global hypomethylation
lead to an activation of the oncogenic Wnt signaling path- way. Moreover, cell cycle related gene mutations in TP53, RB1, MDM2, and CDKN2A are also commonly seen. TP53 mutations alone are found in 20% of ACCs, and the deleteri- ous nature of the mutations abrogates the normal function of the P53 protein, including cell cycle control, DNA repair, as well as regulation of cellular aging and apoptosis (Fig. 39) [213]. Moreover, patients with germline TP53 mutations predispose for the Li-Fraumeni syndrome, in which patients have an increased risk of developing ACC-thus further solidifying the association between this gene and malignant cortical tumorigenesis [214].
Subsets of cases also display mutations in chromatin remodeling genes such as DAXX, ATRX, and MEN1, and some may also exhibit PKA pathway associated mutations (PRKAR1A) [127, 202, 215, 216].
In terms of chromosomal events, loss of the maternal 11p15 allele adjoined by paternal allele duplication is com- monly noted in ACC [217, 218]. This region encompasses the H19 and IGF2 genes, which are imprinted and thus
expressed selectively from the maternal and paternal allele respectively [219]. This selective loss leads to the down- regulation of H19, a gene encoding a long non-coding RNA with tumor suppressor abilities, and cause up-regulation of oncogenic IGF2. Of note, Beckwith-Wiedemann syndrome patients display uniparenteral disomy (with two inherited paternal alleles) of this locus and display an increased risk of developing ACC. Apart from this chromosomal aberrancy, ACCs are either seen with whole chromosomal losses, or with numerous copy number alterations and whole-genome doubling (Fig. 40) [127].
Next-generation sequencing techniques have prompted a considerable leap in our understanding of ACCs, in which several molecular subclassification schemes with prognostic relevance have been presented [127, 174, 175, 202, 215, 220-222]. Although the studies differ in terms of case numbers and techniques employed, adrenal cortical carcinomas adhere to either low-, intermediate-, or high- risk clusters when profiling their mutational, expressional, DNA methylation, and gross chromosomal landscapes
Fig. 39 P53 normal functions and effects of TP53 mutations. In the wild-type state, P53 is activated upon DNA damage and inhibited via oncogene activation. P53 has many important cellular roles, including the regulation of cell cycle progression, DNA repair as well as regula-
P53 normal functions and effects of TP53 mutations
P53 wildtype pathway
Aberrant P53 pathway
G1
G1
M
M
S
DNA damage
G2
G2
S
DNA damage
Cell cycle arrest
Cell cycle progression
P53
DNA repair
Mutant P53
Inhibition of DNA repair
MDM2
MDM2
Senescence
Inhibition of senescence
ARF
ARF
Apoptosis
Inhibition of apoptosis
Oncogene activation
Oncogene activation
tion of cellular senescence and apoptosis. When inactivated by muta- tions or deletions, DNA damage accumulate, and cell cycle progres- sion and inhibition of apoptosis is seen. Created with BioRender.com
Molecular risk triaging of adrenal cortical carcinoma
Low disease progression rate
Rarely Wnt/P53 pathway mutations
Intermediate disease progression rate
Often Wnt pathway mutations
High disease progression rate
Often Wnt/P53 pathway mutations
CoCI
CoC II
CoC III
Expressional cluster C1B
Expressional cluster C1A
Expressional cluster C1A
Whole- chromosomal losses
Whole- chromosomal losses
Whole- genome doubling
Me
Me
Me
PROMOTER
GENE
PROMOTER
GENE
PROMOTER
GENE
CIMP low
CIMP intermediate
CIMP high
Low risk ACCs
Intermediate risk ACCs
High risk ACCs
(Fig. 40) [127, 215, 223]. While low progression rate tumors rarely exhibit Wnt/P53 pathway mutations, display low levels of DNA methylation (“CpG island methylator phenotype (CIMP) low”) and associate to mRNA expres- sional clusters normally associated to a more indolent clinical course, high-risk ACCs carry frequent Wnt/P53 pathway mutations, an expression pattern often associ- ated to worse outcome, a CIMP-high profile as well as extensive chromosomal alterations with whole-genome doubling (Fig. 40) [127].
While the pan-genomic classification of ACC is promis- ing for the future integration in clinical work-up of these lesions, there is still a gap between what we are able to do in the research laboratory compared to our everyday clinical routine. The new WHO classification encourages diagnosticians to provide common immunohistochemical correlates of poor prognostic molecular clusters (e.g., P53 and beta-catenin); however, routine use of targeted genetic analyses and/or prognostic molecular analyses (e.g., tran- scriptome or methylome studies) is anticipated to aid the management in the near future. Indeed, the TCGA study on ACCs identified a smaller methylation assay consist- ing of 68 probes may be helpful in the identification of high-risk ACCs [127], and subsequent studies provided
low phenotype, CoC III tumors are considered high risk lesions, and associate to a different expressional cluster and carry frequent Wnt/ P53 signaling pathway mutations, a hypermethylated genome and fre- quent chromosomal aberrancies, including whole-genome doubling. Created with BioRender.com
additional value to the assessment of the G0/G1 Switch 2 (G0S2) gene hypermethylation as a surrogate marker for CIMP-high cases endowed with poor prognosis [127, 173].
Question 12: What are Correlates of Genetic Predisposition in Adrenal Cortical Proliferations?
Although most adrenal cortical proliferations are clonal expansions due to the acquisition of somatic mutations, sub- sets of cases arise in patients with an underlying genetic pre- disposition. Basic knowledge regarding syndromic variants of adrenal cortical lesions is imperative in order to detect these cases in the clinical setting, allowing genetic coun- seling and adequate patient follow-up. In this section, a brief overview of germline alterations coupled to the development of adrenal cortical disease is summarized.
Congenital Adrenal Hyperplasia (CAH)
CAH is an autosomal recessive genetic disorder in which patients display germline mutations in genes encoding vari- ous enzymes in the adrenal cortical steroidogenesis pathway.
The dominant gene in this aspect is CYP21A2, which is found mutated in 95-99% of CAH patients [224, 225]. The CYP21A2 gene encodes the 21-hydroxylase enzyme involved in both the production of mineralocorticoids and glucocorticoids, and individuals with bi-allelic mutations in CYP21A2 will impede the ability to produce aldoster- one and cortisol, while instead driving excess production of androgens [226]. This may cause significant virilization. Also, the reduced production of cortisol will lift the nega- tive feedback on the hypothalamus-pituitary axis, thereby leading to elevated ACTH levels, which in turn will cause the adrenals to become hyperplastic (Fig. 41). Mutations in other genes may also cause CAH, including CYP11B1 (encoding 11-beta-hydroxylase), HSD3B2 (encoding 3-beta- hydroxysteroid dehydrogenase), and CYP17A1 (encod- ing 17-alpha-hydroxylase) [224]. Adrenal cortical tumor formation is noted in approximately 24% of patients with genetically confirmed CAH, and almost 40% of patients may exhibit adrenal myelolipoma (Fig. 41) [227, 228]. The reason for the overrepresentation of myelolipomas in CAH is not known.
Bilateral Adrenocortical Nodular Disease
The term “bilateral adrenocortical nodular disease” com- prises cortisol-producing primary bilateral micronodular adrenal cortical disease (nodules < 10 mm) and primary bilateral macronodular adrenal cortical disease (nod- ules> 10 mm), of which the former can be sub-divided into primary pigmented micronodular adrenal cortical disease (PPNAD) and isolated micronodular adrenal cortical disease
A
B
C
(i-MAD). Irrespectively of entity, these patients regularly exhibit a germline variant in a susceptibility gene, which is then followed by a “second hit” occurring on the trans allele. PPNAD is coupled to Carney complex, a syndrome of car- diac myxomas, spotty pigmentation and endocrine overactiv- ity, including adrenal cortical lesions [86]. When occurring in the context of Carney complex (“c-PPNAD”), mutations in genes regulating the PKA pathway are predominant, such as PRKAR1A (most common alteration in c-PPNAD and isolated PPNAD (i-PPNAD) followed by PRKACA gene aberrancies and CNC2 locus alterations [5, 81]. In a similar manner, germline variants in PKA pathway related genes PDE11A and PDE8B may cause i-MAD [4, 15, 229, 230].
Primary bilateral macronodular adrenal cortical disease (formerly known primary bilateral macronodular adrenal cortical hyperplasia) is composed of independent clonal expansions in which the patients usually carry germline mutations in ARMC5, MEN1, FH, APC, GNAS, PDE8B or PDE11A [4, 5, 7-14, 92, 172]. ARMC5 mutations are most commonly seen (occurring in 25-55% of cases), with addi- tional somatic alterations found in the trans allele in each independent nodule-strongly arguing for multiclonal tumor development rather than a “hyperplastic” phenomenon. Interestingly, patients with primary bilateral macronodular adrenal cortical disease carrying ARMC5 mutations more often present with larger adrenals and a more pronounced hypercortisolism than those without ARMC5 mutations [9].
Adrenocortical Adenoma and Carcinoma
Genetic syndromes predisposing for adrenal cortical tumors are summarized in Fig. 42. Adrenal cortical adenomas are reported as unusual manifestations of the Li-Fraumeni, MEN1, FAP, Beckwith Wiedemann and Carney complex syndromes. Moreover, in terms of aldosterone-producing adenomas, subsets of patients may present with a family history of primary aldosteronism in an autosomal dominant pattern with several affected first-degree relatives. These syndromes (familial hyperaldosteronism, FHA) include FHA type 1 (germline CYP11B1/CYP11B2 chimeric fusions) [231], FHA type II (germline CLCN2 mutations) [232], FHA type III (germline KCNJ5 mutations) [186] and FHA type IV (germline CACNA1H mutations) [191]. Moreover, germline CACNA1D mutations may also cause early onset primary aldosteronism with various neurological abnormalities; also known as the “PASNA” syndrome [189].
Hereditary conditions in which ACCs are overrepresented include Li-Fraumeni, Lynch, MEN1, Beckwith Wiedemann, Carney complex and NF1 syndromes [4]. Overall, approxi- mately 10% of ACCs are expected to arise in a hereditary setting [233]. The most common syndromic manifestation is Li-Fraumeni syndrome, which may be evident in 50-80% of children that present with ACCs, in addition to 3-5% of
Hereditary syndromes coupled to adrenal cortical neoplasia
| Adrenal cortical adenoma | Adrenal cortical carcinoma | ||||
|---|---|---|---|---|---|
| Syndrome | Gene | Prevalence in ACA patients | Syndrome | Gene | Prevalence in ACC patients |
| Li-Fraumeni | TP53 | <1% | Li-Fraumeni | TP53 | 3-5% (adults) 50-80% (pediatric) |
| Multiple endocrine neoplasia 1 | MEN1 | <1% | Lynch | MSH2, MSH6, MLH1, PMS2 | 3% (adults) |
| Familial adenomatous polyposis | APC | <1% | 1 Multiple endocrine neoplasia 1 | MEN1 | 2% (adults) |
| Beckwith Wiedemann | H19 IGF2 | <1% | Familial adenomatous polyposis | APC | <1% |
| Carney complex | PRKAR1A | <1% | Beckwith Wiedemann | H19 IGF2 | <1% |
| FHA type: | |||||
| I | CYP11B1, CYP11B2 | <1% | Carney complex | PRKAR1A | <1% |
| II | CLCN2 | <1% | |||
| III | KCNJ5 | <1% | Neurofibromatosis type 1 | NF1 | <1% |
| IV | CACNA1H | <1% | |||
| PASNA | CACNA1D | <1% | |||
Fig. 42 Hereditary syndromes coupled to adrenal cortical neoplasia. Schematic overview of the most common syndromes associated to the development of adrenal cortical adenoma (left) and adrenal cor-
tical carcinoma (right). FHA, familial hyperaldosteronism syndrome; PASNA, primary aldosteronism, seizures, and neurologic abnormali- ties. Created with BioRender.com
Consent for Publication All authors consent to publication.
Conflict of Interest Dr. Ozgur Mete is the Editor-in-Chief of Endo- crine Pathology. Dr. Lori A. Erickson is the Senior Associate Editor of Endocrine Pathology. This review article was handled by an independ- ent editor and peer-reviewed as per the journal standards. The remain- ing authors declare that they have no competing interest.
References
1. Hodgson A, Pakbaz S, Mete O (2019) A Diagnostic Approach to Adrenocortical Tumors. Surg Pathol Clin 12:967-995 . https:// doi.org/10.1016/j.path.2019.08.005
2. Mete O, Asa SL (2013) Precursor lesions of endocrine system neoplasms. Pathology 45:316-330 . https://doi.org/10.1097/PAT. 0b013e32835f45c5
3. van Nederveen FH, de Krijger RR (2007) Precursor lesions of the adrenal gland. Pathobiology 74:285-290 . https://doi.org/10. 1159/000105811
4. Juhlin CC, Bertherat J, Giordano TJ, Hammer GD, Sasano H, Mete O (2021) What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Trans- lational Genomics. Endocr Pathol 32:102-133 . https://doi.org/ 10.1007/s12022-021-09667-0
adults. Furthermore, approximately 3% of adults developing this disease are found be Lynch syndrome patients carry- ing inactivating germline mutations in one out of the well- known mismatch repair genes MSH2, MSH6, MLH1, and PSM2 [180]. Since mutations in these genes are coupled to absent immunoreactivity for the corresponding proteins, MSH2, MSH6, MLH1 and PMS2 immunohistochemistry may therefore be an efficient way to identify cases in need of genetic counseling [1, 179]. Moreover, germline SDHx variants have been coupled to the development of ACCs, but these findings need additional verification [184]. The role of ancillary biomarkers with respect to germline screening are discussed in Question 10; however, careful assessment of the non-tumorous adrenal cortex may also help to distinguish c-PPNAD-related ACCs [234]. Given the overall rarity of ACCs, genetic counseling may be considered for all patients irrespective of the age of the patient [233].
Declarations
Ethics Approval Not applicable.
5. Mete O, Duan K (2018) The Many Faces of Primary Aldoster- onism and Cushing Syndrome: A Reflection of Adrenocortical Tumor Heterogeneity. Front Med (Lausanne) 5:54 . https://doi. org/10.3389/fmed.2018.00054
6. Kamilaris CDC, Hannah-Shmouni F, Stratakis CA (2020) Adren- ocortical tumorigenesis: Lessons from genetics. Best Pract Res Clin Endocrinol Metab 34:101428 . https://doi.org/10.1016/j. beem.2020.101428
7. Vaduva P, Bonnet F, Bertherat J (2020) Molecular Basis of Pri- mary Aldosteronism and Adrenal Cushing Syndrome. J Endocr Soc 4:bvaa075 . https://doi.org/10.1210/jendso/bvaa075
8. Hannah-Shmouni F, Faucz FR, Stratakis CA (2016) Alterations of Phosphodiesterases in Adrenocortical Tumors. Front Endocrinol (Lausanne) 7:111 . https://doi.org/10.3389/fendo.2016.00111
9. Espiard S, Drougat L, Libé R, Assié G, Perlemoine K, Guignat L, Barrande G, Brucker-Davis F, Doullay F, Lopez S, Sonnet E, Torremocha F, Pinsard D, Chabbert-Buffet N, Raffin-Sanson M-L, Groussin L, Borson-Chazot F, Coste J, Bertagna X, Stratakis CA, Beuschlein F, Ragazzon B, Bertherat J (2015) ARMC5 Mutations in a Large Cohort of Primary Macronodular Adrenal Hyperplasia: Clinical and Functional Consequences. J Clin Endocrinol Metab 100:E926-935 . https://doi.org/10.1210/jc.2014-4204
10. Assié G, Libé R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, Barreau O, Lefèvre L, Sibony M, Guignat L, Rodriguez S, Perlemoine K, René-Corail F, Letourneur F, Trabulsi B, Poussier A, Chabbert-Buffet N, Borson-Chazot F, Groussin L, Bertagna X, Stratakis CA, Ragazzon B, Bertherat J (2013) ARMC5 mutations in macronodular adrenal hyperplasia with Cushing’s syndrome. N Engl J Med 369:2105-2114 . https:// doi.org/10.1056/NEJMoa1304603
11. Gaujoux S, Pinson S, Gimenez-Roqueplo A-P, Amar L, Ragazzon B, Launay P, Meatchi T, Libé R, Bertagna X, Audebourg A, Zucman- Rossi J, Tissier F, Bertherat J (2010) Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clin Cancer Res 16:5133-5141 . https://doi.org/10.1158/ 1078-0432.CCR-10-1497
12. Hsiao H-P, Kirschner LS, Bourdeau I, Keil MF, Boikos SA, Verma S, Robinson-White AJ, Nesterova M, Lacroix A, Stratakis CA (2009) Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secre- tion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J Clin Endocrinol Metab 94:2930-2937 . https://doi.org/10.1210/jc. 2009-0516
13. Ventura M, Melo M, Carrilho F (2019) Outcome and long-term follow-up of adrenal lesions in multiple endocrine neoplasia type 1. Arch Endocrinol Metab 63:516-523 . https://doi.org/ 10.20945/2359-3997000000170
14. Villares Fragoso MCB, Wanichi IQ, Cavalcante IP, Mariani BM de P (2016) The Role of gsp Mutations on the Devel- opment of Adrenocortical Tumors and Adrenal Hyperplasia. Front Endocrinol (Lausanne) 7:104 . https://doi.org/10.3389/ fendo.2016.00104
15. Duan K, Gomez Hernandez K, Mete O (2015) Clinicopatho- logical correlates of adrenal Cushing’s syndrome. J Clin Pathol 68:175-186 . https://doi.org/10.1136/jclinpath-2014-202612
16. Williams TA, Gomez-Sanchez CE, Rainey WE, Giordano TJ, Lam AK, Marker A, Mete O, Yamazaki Y, Zerbini MCN, Beuschlein F, Satoh F, Burrello J, Schneider H, Lenders JWM, Mulatero P, Castellano I, Knösel T, Papotti M, Saeger W, Sasano H, Reincke M (2021) International Histopathology Consensus for Unilateral Primary Aldosteronism. J Clin Endocrinol Metab 106:42-54 . https://doi.org/10.1210/clinem/dgaa484
17. Volpe C, Hamberger B, Zedenius J, Juhlin CC (2020) Impact of immunohistochemistry on the diagnosis and management of
primary aldosteronism: An important tool for improved patient follow-up. Scand J Surg 109:133-142 . https://doi.org/10.1177/ 1457496918822622
18. Mete O, Asa SL, Giordano TJ, Papotti M, Sasano H, Volante M (2018) Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms. Endocr Pathol 29:137-149 . https://doi.org/10.1007/ s12022-018-9525-8
19. Nakamura Y, Maekawa T, Felizola SJA, Satoh F, Qi X, Velarde- Miranda C, Plonczynski MW, Ise K, Kikuchi K, Rainey WE, Gomez-Sanchez EP, Gomez-Sanchez CE, Sasano H (2014) Adre- nal CYP11B1/2 expression in primary aldosteronism: immuno- histochemical analysis using novel monoclonal antibodies. Mol Cell Endocrinol 392:73-79 . https://doi.org/10.1016/j.mce.2014. 05.002
20. Nanba K, Tsuiki M, Sawai K, Mukai K, Nishimoto K, Usui T, Tagami T, Okuno H, Yamamoto T, Shimatsu A, Katabami T, Okumura A, Kawa G, Tanabe A, Naruse M (2013) Histopatho- logical diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry. J Clin Endocrinol Metab 98:1567-1574 . https://doi.org/10.1210/jc.2012-3726
21. Volpe C, Höög A, Ogishima T, Mukai K, Lu M, Thorén M, Hamberger B (2013) Immunohistochemistry improves histopathologic diagno- sis in primary aldosteronism. J Clin Pathol 66:351-354 . https://doi. org/10.1136/jclinpath-2012-201287
22. Falco EC, Daniele L, Metovic J, Bollito E, De Rosa G, Volante M, Papotti M (2021) Adrenal Rests in the Uro-genital Tract of an Adult Population. Endocr Pathol 32:375-384 . https://doi.org/ 10.1007/s12022-021-09685-y
23. Engels M, Span PN, van Herwaarden AE, Sweep FCGJ, Stikkelbroeck NMML, Claahsen-van der Grinten HL (2019) Testicular Adrenal Rest Tumors: Current Insights on Prevalence, Characteristics, Ori- gin, and Treatment. Endocr Rev 40:973-987 . https://doi.org/10. 1210/er.2018-00258
24. Lolis E, Juhlin CC, Nordenström A, Falhammar H (2018) Exten- sive Bilateral Adrenal Rest Testicular Tumors in a Patient With 36-Hydroxysteroid Dehydrogenase Type 2 Deficiency. J Endocr Soc 2:513-517 . https://doi.org/10.1210/js.2018-00082
25. Ma L, Xia Y, Wang L, Liu R, Huang X, Ye T, Zhang L, Zhu Q, Li J, Jiang Y (2019) Sonographic features of the testicular adrenal rests tumors in patients with congenital adrenal hyperplasia: a single-center experience and literature review. Orphanet J Rare Dis 14:242 . https://doi.org/10.1186/s13023-019-1231-1
26. Corica D, Bottari A, Aversa T, Caudo D, Galletta K, Micalizzi MF, Pajno GB, Wasniewska M, Ascenti G (2019) An unusual epididymal localization of Testicular Adrenal Rest Tumor in an adolescent with congenital adrenal hyperplasia. Endocrine 66:695-698 . https://doi.org/10.1007/s12020-019-01986-x
27. Bouzidi L, Triki M, Charfi S, Ameur HB, Dhaou MB, Bouaziz T, Boudawara T (2021) Incidental Finding of Bilateral Ovarian Adre- nal Rest Tumor in a Patient With Congenital Adrenal Hyperplasia: A Case Report and Brief Review. Pediatr Dev Pathol 24:137-141 . https://doi.org/10.1177/1093526620980614
28. Burman P, Falhammar H, Waldenström E, Sundin A, Bitzén U (2021) 11C-Metomidate PET/CT Detected Multiple Ectopic Adrenal Rest Tumors in a Woman With Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab 106:e675-e679 . https:// doi.org/10.1210/clinem/dgaa870
29. Uyanıkoglu H, Ozer G, Kahraman S (2020) A spontaneous preg- nancy and live birth in a woman with primary infertility follow- ing the excision of an ovarian adrenal rest tumor: A rare case. Clin Exp Reprod Med 47:319-322 . https://doi.org/10.5653/ cerm.2020.03692
30. Sisto JM, Liu FW, Geffner ME, Berman ML (2018) Para-ovarian adrenal rest tumors: gynecologic manifestations of untreated con- genital adrenal hyperplasia. Gynecol Endocrinol 34:644-646 . https://doi.org/10.1080/09513590.2018.1441399
31. Chew KT, Abu MA, Arifuddin Y, Mohamed Ismail NA, Nasir NAM, Mohammed F, Nur Azurah AG (2017) Ectopic adrenal tis- sue associated with borderline mucinous cystadenoma of ovary: a case report with review of the literature. Horm Mol Biol Clin Investig 32:/j/hmbci.2017.32.issue-3/hmbci-2017-0021/hmbci- 2017-0021.xml . https://doi.org/10.1515/hmbci-2017-0021
32. Chen H-D, Huang L-E, Zhong Z-H, Su Z, Jiang H, Zeng J, Liu J-C (2017) Ovarian Adrenal Rest Tumors Undetected by Imaging Studies and Identified at Surgery in Three Females with Con- genital Adrenal Hyperplasia Unresponsive to Increased Hormone Therapy Dosage. Endocr Pathol 28:146-151 . https://doi.org/10. 1007/s12022-016-9461-4
33. Tiosano D, Vlodavsky E, Filmar S, Weiner Z, Goldsher D, Bar- Shalom R (2010) Ovarian adrenal rest tumor in a congenital adrenal hyperplasia patient with adrenocorticotropin hyperse- cretion following adrenalectomy. Horm Res Paediatr 74:223-228 . https://doi.org/10.1159/000295722
34. Tingi E, Ogah J (2018) Ectopic adrenal rest cells of the fallopian tube: a case report and review of the literature. J Obstet Gynaecol 38:578-579 . https://doi.org/10.1080/01443615.2017.1379063
35. Khandakar B, Dey S, Ray PS, Sarkar R, Bhattacharyya P (2015) Ectopic Paratubal Adrenal Cell Rest Associated with Mucinous Cystadenoma of Ovary. J Clin Diagn Res 9:ED13-14 . https:// doi.org/10.7860/JCDR/2015/15411.6638
36. N Schaumann K Hussein 2020 Hepatic and Adrenocortical Choristomas in the Placenta Fetal Pediatr Pathol 1-10 . https:// doi.org/10.1080/15513815.2020.1792594
37. Kasajima A, Nakamura Y, Adachi Y, Takahashi Y, Fujishima F, Chiba Y, Uehara S, Watanabe M, Sasano H (2014) Oncocytic adrenocortical neoplasm arising from adrenal rest in the broad ligament of the uterus. Pathol Int 64:183-188 . https://doi.org/ 10.1111/pin.12154
38. Sasano H, Sato S, Yajima A, Akama J, Nagura H (1997) Adrenal rest tumor of the broad ligament: case report with immunohisto- chemical study of steroidogenic enzymes. Pathol Int 47:493-496 . https://doi.org/10.1111/j.1440-1827.1997.tb04529.x
39. Yokoyama H, Adachi T, Tsubouchi K, Tanaka M, Sasano H (2013) Non-functioning adrenocortical carcinoma arising in an adrenal rest: immunohistochemical study of an adult patient. Tohoku J Exp Med 229:267-270 . https://doi.org/10.1620/tjem. 229.267
40. Akishima-Fukasawa Y, Yoshihara A, Ishikawa Y, Watanabe N, Hiroi N, Akasaka Y, Sasano H, Ishii T, Yoshino G (2011) Malignant adrenal rest tumor of the retroperitoneum producing adrenocortical steroids. Endocr Pathol 22:112-117 . https://doi. org/10.1007/s12022-011-9152-0
41. Cornejo KM, Afari HA, Sadow PM (2017) Adrenocortical Car- cinoma Arising in an Adrenal Rest: a Case Report and Review of the Literature. Endocr Pathol 28:165-170 . https://doi.org/10. 1007/s12022-017-9472-9
42. Senescende L, Bitolog PL, Auberger E, Zarzavadjian Le Bian A, Cesaretti M (2016) Adrenal ectopy of adult groin region: a sys- tematic review of an unexpected anatomopathologic diagnosis. Hernia 20:879-885 . https://doi.org/10.1007/s10029-016-1535-1
43. Ketata S, Ketata H, Sahnoun A, FakhFakh H, Bahloul A, Mhiri MN (2008) Ectopic adrenal cortex tissue: an incidental finding during inguinoscrotal operations in pediatric patients. Urol Int 81:316-319 . https://doi.org/10.1159/000151411
44. Drut R, Quijano G, Altamirano ME, Jones MC, Maffessoli OB (2006) Vascular malformation and choroid plexus adrenal heterotopia: new findings in Beckwith-Wiedemann syndrome? Fetal Pediatr Pathol 25:191-197 . https://doi.org/10.1080/ 15513810601015704
45. Giner J, Esteban I, Carceller F, Saceda J, Regojo RM (2017) Spinal adrenal cortical adenoma associated with Beckwith- Wiedemann syndrome: case report and review of the literature.
Childs Nerv Syst 33:1009-1013 . https://doi.org/10.1007/ s00381-017-3397-y
46. Makino K, Kojima R, Nakamura H, Morioka M, Iyama K, Shigematsu K, Kuratsu J (2010) Ectopic adrenal cortical ade- noma in the spinal region: case report and review of the litera- ture. Brain Tumor Pathol 27:121-125 . https://doi.org/10.1007/ s10014-010-0270-z
47. Mitchell A, Scheithauer BW, Sasano H, Hubbard EW, Ebersold MJ (1993) Symptomatic intradural adrenal adenoma of the spinal nerve root: report of two cases. Neurosurgery 32:658-661; dis- cussion 661-662 . https://doi.org/10.1227/00006123-199304000- 00024
48. Marchevsky AM (1995) Lung tumors derived from ectopic tissues. Semin Diagn Pathol 12:172-184
49. Armin A, Castelli M (1984) Congenital adrenal tissue in the lung with adrenal cytomegaly. Case report and review of the literature. Am J Clin Pathol 82:225-228 . https://doi.org/10. 1093/ajcp/82.2.225
50. Turan H, Tarçın G, Mete Ö, Sinoplu AB, Evliyaoğlu SO, Öz B, Ercan O (2021) SILENT CORTICOTROPH TUMOR WITH ADRENOCORTICAL CHORISTOMA IN AN ELEVEN- YEAR-OLD BOY. J Clin Res Pediatr Endocrinol. https://doi. org/10.4274/jcrpe.galenos.2021.2020.0258
51. Mete O, Ng T, Christie-David D, McMaster J, Asa SL (2013) Silent corticotroph adenoma with adrenal cortical choristoma: a rare but distinct morphological entity. Endocr Pathol 24:162- 166 . https://doi.org/10.1007/s12022-013-9256-9
52. Uğur Kılınç AN, Bayramoğlu Z, Ünlü Y, Keçeli AM, Dönmez Mİ (2021) Incidental ectopic adrenal cortical tissue: Retrospec- tive analysis of 16 patients. J Pediatr Urol 17:258.e1-258.e6 . https://doi.org/10.1016/j.jpurol.2020.12.027
53. Yousif MQ, Salih ZT, De Young BR, Qasem SA (2018) Dif- ferentiating Intrarenal Ectopic Adrenal Tissue From Renal Cell Carcinoma in the Kidney. Int J Surg Pathol 26:588-592 . https://doi.org/10.1177/1066896918779449
54. Shigematsu K, Toriyama K, Kawai K, Takahara O (2007) Ectopic adrenal tissue in the thorax: a case report with in situ hybridization and immunohistochemical studies. Pathol Res Pract 203:543-548 . https://doi.org/10.1016/j.prp.2007.03.006
55. Yu H, He Y (2020) Hepatic adrenal adenoma-rare tumor on right lobe of liver: a case report and literature review. BMC Surg 20:128 . https://doi.org/10.1186/s12893-020-00780-1
56. Ren P-T, Fu H, He X-W (2013) Ectopic adrenal cortical ade- noma in the gastric wall: case report. World J Gastroenterol 19:778-780 . https://doi.org/10.3748/wjg.v19.i5.778
57. Caliò A, Warfel KA, Eble JN (2019) Papillary Adenomas and Other Small Epithelial Tumors in the Kidney: An Autopsy Study. Am J Surg Pathol 43:277-287 . https://doi.org/10.1097/ PAS.0000000000001189
58. Lottrup G, Nielsen JE, Skakkebæk NE, Juul A, Rajpert-De Meyts E (2015) Abundance of DLK1, differential expres- sion of CYP11B1, CYP21A2 and MC2R, and lack of INSL3 distinguish testicular adrenal rest tumours from Leydig cell tumours. Eur J Endocrinol 172:491-499 . https://doi.org/10. 1530/EJE-14-0810
59. Baba Y, Beppu T, Imai K, Masuda T, Iyama K-I, Sasano H, Baba H (2008) A case of adrenal rest tumor of the liver: Radio- logical imaging and immunohistochemical study of steroidogenic enzymes. Hepatol Res 38:1154-1158 . https://doi.org/10.1111/j. 1872-034X.2008.00360.x
60. Arai K, Muro H, Suzuki M, Oba N, Ito K, Sasano H (2000) Adrenal rest tumor of the liver: a case report with immunohisto- chemical investigation of steroidogenesis. Pathol Int 50:244-248 . https://doi.org/10.1046/j.1440-1827.2000.01029.x
61. Issam R, Amine MM, Meriam T, Ahmed C, Mehdi B, Mourad HS (2021) Lymphangiomatous endothelial cyst of the adrenal
gland: A case report. Urol Case Rep 39:101859 . https://doi.org/ 10.1016/j.eucr.2021.101859
62. Gubbiotti MA, Livolsi V, Montone K, Baloch Z (2021) A Cyst- ematic Analysis of the Adrenal Gland. Am J Clin Pathol aqab156 . https://doi.org/10.1093/ajcp/aqab156
63. Zheng W, Fung K-M, Cheng L, Osunkoya AO (2018) Benign vascular tumors, cysts, and pseudocysts of the adrenal gland: a contemporary multi-institutional clinicopathological analysis of 55 cases. Hum Pathol 82:95-102 . https://doi.org/10.1016/j. humpath.2018.07.013
64. Cavallaro G, Crocetti D, Paliotta A, De Gori A, Tarallo MR, Letizia C, De Toma G (2015) Cystic adrenal lesions: clinical and surgical management. The experience of a referral centre. Int J Surg 13:23-26 . https://doi.org/10.1016/j.ijsu.2014.11.023
65. Erickson LA, Lloyd RV, Hartman R, Thompson G (2004) Cystic adrenal neoplasms. Cancer 101:1537-1544 . https://doi.org/10. 1002/cncr.20555
66. Mete O, Asa SL (2016) Endocrine pathology. Cambridge Uni- versity Press, Cambridge
67. Chien H-P, Chang Y-S, Hsu P-S, Lin J-D, Wu Y-C, Chang H-L, Chuang C-K, Tsuei K-H, Hsueh C (2008) Adrenal cystic lesions: a clinicopathological analysis of 25 cases with proposed his- togenesis and review of the literature. Endocr Pathol 19:274-281 . https://doi.org/10.1007/s12022-008-9046-y
68. Bouchaala H, Mejdoub I, Mseddi MA, Kammoun O, Rebai N, Slimen MH (2021) Giant primary hydatid cyst of the adrenal gland: A rare case report. Urol Case Rep 36:101580 . https://doi. org/10.1016/j.eucr.2021.101580
69. Olowu AA, Alzehairy AA (2021) A huge haemorrhagic suprare- nal pseudocyst: an unusual presentation of a rare condition. BMJ Case Rep 14:e235158 . https://doi.org/10.1136/bcr-2020-235158
70. Zouari S, Marouene C, Bibani H, Saadi A, Sellami A, Haj Kacem L, Blel A, Bouzouita A, Derouiche A, Ben Slama R, Rammeh S, Ayed H, Chebil M (2020) Primary Hydatid Cyst of the adrenal gland: A case report and a review of the literature. Int J Surg Case Rep 70:154-158 . https://doi.org/10.1016/j.ijscr.2020.04.073
71. Akbulut S (2016) Incidentally detected hydatid cyst of the adre- nal gland: A case report. World J Clin Cases 4:269-272 . https:// doi.org/10.12998/wjcc.v4.i9.269
72. Suh J, Heimann A, Cohen H (2008) True adrenal mesothelial cyst in a patient with flank pain and hematuria: a case report. Endocr Pathol 19:203-205 . https://doi.org/10.1007/s12022-008-9026-2
73. Goel D, Enny L, Rana C, Ramakant P, Singh K, Babu S, Mishra A (2021) Cystic adrenal lesions: A report of five cases. Cancer Rep (Hoboken) 4:e1314 . https://doi.org/10.1002/cnr2.1314
74. Sebastiano C, Zhao X, Deng F-M, Das K (2013) Cystic lesions of the adrenal gland: our experience over the last 20 years. Hum Pathol 44:1797-1803 . https://doi.org/10.1016/j.humpath.2013. 02.002
75. Romero-Rojas A, Bella-Cueto MR, Meza-Cabrera IA, Cabezuelo- Hernández A, García-Rojo D, Vargas-Uricoechea H, Cameselle- Teijeiro J (2013) Ectopic thyroid tissue in the adrenal gland: a report of two cases with pathogenetic implications. Thyroid 23:1644-1650 . https://doi.org/10.1089/thy.2013.0063
76. Tahri A, Abdellaoui W, Benyakhlef S, Boujtat K, Mahroug I, Kamaoui I, Barki A, Kettani F, Rouf S, Latrech H (2021) An Uncommon Presentation of Adrenal Cyst with Subclinical Cush- ing’s Syndrome: A Diagnosis Dilemma. Case Rep Endocrinol 2021:6662492 . https://doi.org/10.1155/2021/6662492
77. Tagawa H, Yamada T, Miyakawa T, Aida Y, Sekiguchi Z (2021) A collision between vascular adrenal cyst and adrenocortical adenoma. Radiol Case Rep 16:1294-1299 . https://doi.org/10. 1016/j.radcr.2021.02.067
78. Babaya N, Okuda Y, Noso S, Hiromine Y, Taketomo Y, Niwano F, Ueda K, Tanaka Y, Yamazaki Y, Sasano H, Kawabata Y, Ohno Y, Ikegami H (2021) A Rare Case of Adrenal Cysts Associated
With Bilateral Incidentalomas and Diffuse Hyperplasia of the Zona Glomerulosa. J Endocr Soc 5:bvaa184 . https://doi.org/10. 1210/jendso/bvaa184
79. Sakaue T, Okuno Y, Mukai K, Fujita S, Kozawa J, Nishizawa H, Matsuoka T-A, Iwahashi H, Norikazu M, Yamazaki Y, Sasano H, Otsuki M, Shimomura I (2021) Coincidence of Large Adrenal Cyst and Prominent Hyporeninemic Hyperaldosteronism. Case Rep Endocrinol 2021:8860498 . https://doi.org/10.1155/2021/ 8860498
80. Sasano H, Miyazaki S, Sawai T, Sasano N, Nagura H, Funahashi H, Aiba M, Demura H (1992) Primary pigmented nodular adren- ocortical disease (PPNAD): immunohistochemical and in situ hybridization analysis of steroidogenic enzymes in eight cases. Mod Pathol 5:23-29
81. Kamilaris CDC, Stratakis CA, Hannah-Shmouni F (2021) Molecular Genetic and Genomic Alterations in Cushing’s Syn- drome and Primary Aldosteronism. Front Endocrinol (Lausanne) 12:632543 . https://doi.org/10.3389/fendo.2021.632543
82. Maillet M, Bourdeau I, Lacroix A (2020) Update on primary micronodular bilateral adrenocortical diseases. Curr Opin Endo- crinol Diabetes Obes 27:132-139 . https://doi.org/10.1097/MED. 0000000000000538
83. Espiard S, Vantyghem M-C, Assié G, Cardot-Bauters C, Raverot G, Brucker-Davis F, Archambeaud-Mouveroux F, Lefebvre H, Nunes M-L, Tabarin A, Lienhardt A, Chabre O, Houang M, Bottineau M, Stroër S, Groussin L, Guignat L, Cabanes L, Feydy A, Bonnet F, North MO, Dupin N, Grabar S, Duboc D, Bertherat J (2020) Frequency and Incidence of Carney Complex Manifestations: A Prospective Multicenter Study With a Three-Year Follow-Up. J Clin Endocrinol Metab 105:dgaa002 . https://doi.org/10.1210/clinem/dgaa002
84. Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L, Libe R, René-Corail F, Stergiopoulos S, Bourdeau I, Bei T, Clauser E, Calender A, Kirschner LS, Bertagna X, Carney JA, Stratakis CA (2009) Mutations in regulatory subunit type 1A of cyclic adenosine 5’-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 differ- ent genotypes. J Clin Endocrinol Metab 94:2085-2091 . https:// doi.org/10.1210/jc.2008-2333
85. Vezzosi D, Tenenbaum F, Cazabat L, Tissier F, Bienvenu M, Carrasco CA, Laloi-Michelin M, Barrande G, Lefebvre H, Hiéronimus S, Tabarin A, Bertagna X, Legmann P, Vantyghem M-C, Bertherat J (2015) Hormonal, Radiological, NP-59 Scintigraphy, and Patho- logical Correlations in Patients With Cushing’s Syndrome Due to Primary Pigmented Nodular Adrenocortical Disease (PPNAD). J Clin Endocrinol Metab 100:4332-4338 . https://doi.org/10.1210/ jc.2015-2174
86. Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL (1985) The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 64:270-283 . https://doi.org/ 10.1097/00005792-198507000-00007
87. Groussin L, Jullian E, Perlemoine K, Louvel A, Leheup B, Luton JP, Bertagna X, Bertherat J (2002) Mutations of the PRKAR1A gene in Cushing’s syndrome due to sporadic primary pigmented nodular adrenocortical disease. J Clin Endocrinol Metab 87:4324-4329 . https://doi.org/10.1210/jc.2002-020592
88. Bourdeau I, Parisien-La Salle S, Lacroix A (2020) Adrenocor- tical hyperplasia: A multifaceted disease. Best Pract Res Clin Endocrinol Metab 34:101386 . https://doi.org/10.1016/j.beem. 2020.101386
89. Rockall AG, Babar SA, Sohaib SAA, Isidori AM, Diaz-Cano S, Monson JP, Grossman AB, Reznek RH (2004) CT and MR imag- ing of the adrenal glands in ACTH-independent cushing syndrome. Radiographics 24:435-452 . https://doi.org/10.1148/rg.242035092
90. Sasano H, Suzuki T, Nagura H (1994) ACTH-independent macronodular adrenocortical hyperplasia: immunohistochemical
and in situ hybridization studies of steroidogenic enzymes. Mod Pathol 7:215-219
91. Burgess JR, Harle RA, Tucker P, Parameswaran V, Davies P, Greenaway TM, Shepherd JJ (1996) Adrenal lesions in a large kindred with multiple endocrine neoplasia type 1. Arch Surg 131:699-702 . https://doi.org/10.1001/archsurg. 1996. 01430190021006
92. Matyakhina L, Freedman RJ, Bourdeau I, Wei M-H, Stergiopoulos SG, Chidakel A, Walther M, Abu-Asab M, Tsokos M, Keil M, Toro J, Linehan WM, Stratakis CA (2005) Hereditary leiomyoma- tosis associated with bilateral, massive, macronodular adrenocorti- cal disease and atypical cushing syndrome: a clinical and molecu- lar genetic investigation. J Clin Endocrinol Metab 90:3773-3779 .https://doi.org/10.1210/jc.2004-2377
93. Zhu J, Cui L, Wang W, Hang X-Y, Xu A-X, Yang S-X, Dou J-T, Mu Y-M, Zhang X, Gao J-P (2013) Whole exome sequencing identifies mutation of EDNRA involved in ACTH-independent macronodular adrenal hyperplasia. Fam Cancer 12:657-667 . https://doi.org/10.1007/s10689-013-9642-y
94. Larose S, Bondaz L, Mermejo LM, Latour M, Prosmanne O, Bourdeau I, Lacroix A (2019) Coexistence of Myelolipoma and Primary Bilateral Macronodular Adrenal Hyperplasia With GIP-Dependent Cushing’s Syndrome. Front Endocrinol (Laus- anne) 10:618 . https://doi.org/10.3389/fendo.2019.00618
95. Lacroix A, Bourdeau I, Lampron A, Mazzuco TL, Tremblay J, Hamet P (2010) Aberrant G-protein coupled receptor expres- sion in relation to adrenocortical overfunction. Clin Endocrinol (Oxf) 73:1-15 . https://doi.org/10.1111/j.1365-2265.2009. 03689.x
96. Mazzuco TL, Thomas M, Martinie M, Cherradi N, Sturm N, Feige J-J, Chabre O (2007) Cellular and molecular abnormalities of a macronodular adrenal hyperplasia causing beta-blocker-sensitive Cushing’s syndrome. Arq Bras Endocrinol Metabol 51:1452-1462 .https://doi.org/10.1590/s0004-27302007000900007
97. Lacroix A, Baldacchino V, Bourdeau I, Hamet P, Tremblay J (2004) Cushing’s syndrome variants secondary to aberrant hor- mone receptors. Trends Endocrinol Metab 15:375-382 . https:// doi.org/10.1016/j.tem.2004.08.007
98. Lacroix A, N’Diaye N, Mircescu H, Hamet P, Tremblay J (1998) Abnormal expression and function of hormone receptors in adre- nal Cushing’s syndrome. Endocr Res 24:835-843 . https://doi. org/10.3109/07435809809032694
99. Duan K, Mete O (2015) Clinicopathologic Correlates of Primary Aldosteronism. Arch Pathol Lab Med 139:948-954 . https://doi. org/10.5858/arpa.2014-0156-RS
100. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello M-J, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F, PAPY Study Investigators (2006) A prospec- tive study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48:2293-2300 . https:// doi.org/10.1016/j.jacc.2006.07.059
101. Mouat IC, Omata K, McDaniel AS, Hattangady NG, Talapatra D, Cani AK, Hovelson DH, Tomlins SA, Rainey WE, Hammer GD, Giordano TJ, Else T (2019) Somatic mutations in adrenocorti- cal carcinoma with primary aldosteronism or hyperreninemic hyperaldosteronism. Endocr Relat Cancer 26:217-225 . https:// doi.org/10.1530/ERC-18-0385
102. Griffin AC, Kelz R, LiVolsi VA (2014) Aldosterone-secreting adrenal cortical carcinoma. A case report and review of the lit- erature. Endocr Pathol 25:344-349 . https://doi.org/10.1007/ s12022-014-9307-x
103. Gomez-Sanchez CE, Qi X, Velarde-Miranda C, Plonczynski MW, Parker CR, Rainey W, Satoh F, Maekawa T, Nakamura Y, Sasano H, Gomez-Sanchez EP (2014) Development of
monoclonal antibodies against human CYP11B1 and CYP11B2. Mol Cell Endocrinol 383:111-117 . https://doi.org/10.1016/j. mce.2013.11.022
104. Gao X, Yamazaki Y, Tezuka Y, Omata K, Ono Y, Morimoto R, Nakamura Y, Suzuki T, Satoh F, Sasano H (2021) Pathology of Aldosterone Biosynthesis and its Action. Tohoku J Exp Med 254:1-15 . https://doi.org/10.1620/tjem.254.1
105. Gao X, Yamazaki Y, Tezuka Y, Omata K, Ono Y, Morimoto R, Nakamura Y, Satoh F, Sasano H (2021) Gender differences in human adrenal cortex and its disorders. Mol Cell Endocrinol 526:111177 . https://doi.org/10.1016/j.mce.2021.111177
106. Yamazaki Y, Omata K, Tezuka Y, Ono Y, Morimoto R, Adachi Y, Ise K, Nakamura Y, Gomez-Sanchez CE, Shibahara Y, Kitamoto T, Nishikawa T, Ito S, Satoh F, Sasano H (2018) Tumor Cell Subtypes Based on the Intracellular Hormonal Activity in KCNJ5-Mutated Aldosterone-Producing Adenoma. Hypertension 72:632-640 . https://doi.org/10.1161/HYPERTENSIONAHA.118.10907
107. Yamazaki Y, Nakamura Y, Omata K, Ise K, Tezuka Y, Ono Y, Morimoto R, Nozawa Y, Gomez-Sanchez CE, Tomlins SA, Rainey WE, Ito S, Satoh F, Sasano H (2017) Histopathological Classification of Cross-Sectional Image-Negative Hyperaldoster- onism. J Clin Endocrinol Metab 102:1182-1192 . https://doi.org/ 10.1210/jc.2016-2986
108. Inoue K, Yamazaki Y, Tsurutani Y, Suematsu S, Sugisawa C, Saito J, Omura M, Sasano H, Nishikawa T (2017) Evaluation of Cortisol Production in Aldosterone-Producing Adenoma. Horm Metab Res 49:847-853 . https://doi.org/10.1055/s-0043-119878
109. Perna V, Taylor NF, Dworakowska D, Schulte K-M, Aylwin S, Al-Hashimi F, Diaz-Cano SJ (2014) Adrenocortical adenomas with regression and myelolipomatous changes: urinary steroid profiling supports a distinctive benign neoplasm. Clin Endocrinol (Oxf) 81:343-349 . https://doi.org/10.1111/cen.12458
110. Duregon E, Volante M, Bollito E, Goia M, Buttigliero C, Zaggia B, Berruti A, Scagliotti GV, Papotti M (2015) Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases. Hum Pathol 46:1799-1807 . https://doi.org/10.1016/j.humpath.2015.08.012
111. Papotti M, Volante M, Duregon E, Delsedime L, Terzolo M, Berruti A, Rosai J (2010) Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibit- ing malignant behavior. Am J Surg Pathol 34:973-983 . https:// doi.org/10.1097/PAS.0b013e3181e2b726
112. Mete O, Asa SL (2012) Morphological distinction of cortisol- producing and aldosterone-producing adrenal cortical adenomas: not only possible but a critical clinical responsibility. Histopa- thology 60:1015-1016; author reply 1016-1017 . https://doi.org/ 10.1111/j.1365-2559.2011.04141.x
113. Nanba AT, Nanba K, Byrd JB, Shields JJ, Giordano TJ, Miller BS, Rainey WE, Auchus RJ, Turcu AF (2017) Discordance between imaging and immunohistochemistry in unilateral pri- mary aldosteronism. Clin Endocrinol (Oxf) 87:665-672 . https:// doi.org/10.1111/cen.13442
114. Wang H, Wang F, Zhang Y, Wen J, Dong D, Chang X, Sun H, Ma X, Cui Y, Chen S, Lu L, Ren W, Tong A, Li Y (2021) Surgi- cal Outcomes of Aldosterone-Producing Adenoma on the Basis of the Histopathological Findings. Front Endocrinol (Lausanne) 12:663096 . https://doi.org/10.3389/fendo.2021.663096
115. Patel KA, Calomeni EP, Nadasdy T, Zynger DL (2014) Adrenal gland inclusions in patients treated with aldosterone antagonists (Spironolactone/Eplerenone): incidence, morphology, and ultra- structural findings. Diagn Pathol 9:147 . https://doi.org/10.1186/ 1746-1596-9-147
116. Del Gaudio AD, Del Gaudio GA (1993) Virilizing adrenocortical tumors in adult women. Report of 10 patients, 2 of whom each had a tumor secreting only testosterone. Cancer 72:1997-2003 . https://doi.org/10.1002/1097-0142(19930915)72:6<1997 :: aid- cncr2820720634>3.0.co;2-1
117. Allolio B, Fassnacht M (2006) Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91:2027- 2037 . https://doi.org/10.1210/jc.2005-2639
118. Fassnacht M, Dekkers O, Else T, Baudin E, Berruti A, de Krijger R, Haak H, Mihai R, Assie G, Terzolo M (2018) European Soci- ety of Endocrinology Clinical Practice Guidelines on the man- agement of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 179:G1-G46 . https://doi.org/10.1530/EJE-18-0608
119. Moreno S, Guillermo M, Decoulx M, Dewailly D, Bresson R, Proye C (2006) Feminizing adreno-cortical carcinomas in male adults. A dire prognosis. Three cases in a series of 801 adrenal- ectomies and review of the literature. Ann Endocrinol (Paris) 67:32-38 . https://doi.org/10.1016/s0003-4266(06)72537-9
120. Mete O, Gucer H, Kefeli M, Asa SL (2018) Diagnostic and Prog- nostic Biomarkers of Adrenal Cortical Carcinoma. Am J Surg Pathol 42:201-213 . https://doi.org/10.1097/PAS.0000000000000943
121. Giordano TJ, Berney D, de Krijger RR, Erickson L, Fassnacht M, Mete O, Papathomas T, Papotti M, Sasano H, Thompson LDR, Volante M, Gill AJ (2020) Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Report- ing. Hum Pathol. https://doi.org/10.1016/j.humpath.2020.10.001
122. Bisceglia M, Ludovico O, Di Mattia A, Ben-Dor D, Sandbank J, Pasquinelli G, Lau SK, Weiss LM (2004) Adrenocortical oncocytic tumors: report of 10 cases and review of the litera- ture. Int J Surg Pathol 12:231-243 . https://doi.org/10.1177/ 106689690401200304
123. Jeremie G, Lifante JC, Chazot FB, Sajous C, Raymond P, Decaussin-Petrucci M (2021) [Myxoid variant of adrenocortical carcinoma]. Ann Pathol 41:186-191 . https://doi.org/10.1016/j. annpat.2020.12.010
124. Hsieh M-S, Chen J-H, Lin L-W (2011) Myxoid adrenal corti- cal carcinoma presenting as primary hyperaldosteronism: case report and review of the literature. Int J Surg Pathol 19:803-807 . https://doi.org/10.1177/1066896909356925
125. de Krijger RR, Papathomas TG (2012) Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants. Virchows Arch 460:9-18 . https:// doi.org/10.1007/s00428-011-1166-y
126. Papathomas TG, Duregon E, Korpershoek E, Restuccia DF, van Marion R, Cappellesso R, Sturm N, Rossi G, Coli A, Zucchini N, Stoop H, Oosterhuis W, Ventura L, Volante M, Fassina A, Dinjens WNM, Papotti M, de Krijger RR (2016) Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immu- nohistochemical, and targeted next-generation sequencing analy- sis. Hum Pathol 58:113-122 . https://doi.org/10.1016/j.humpath. 2016.08.006
127. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu H-T, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MCBV, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA, Cancer Genome Atlas Research Network, Hammer GD, Giordano TJ, Verhaak RGW (2016) Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell 29:723-736 . https://doi. org/10.1016/j.ccell.2016.04.002
128. Weiss LM, Medeiros LJ, Vickery AL (1989) Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13:202-206 . https://doi.org/10.1097/00000478- 198903000-00004
129. Weiss LM (1984) Comparative histologic study of 43 metas- tasizing and nonmetastasizing adrenocortical tumors. Am J
Surg Pathol 8:163-169 . https://doi.org/10.1097/00000478- 198403000-00001
130. Duregon E, Fassina A, Volante M, Nesi G, Santi R, Gatti G, Cappellesso R, Dalino Ciaramella P, Ventura L, Gambacorta M, Dei Tos AP, Loli P, Mannelli M, Mantero F, Berruti A, Terzolo M, Papotti M (2013) The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation study on 245 unpub- lished cases. Am J Surg Pathol 37:1433-1440 . https://doi.org/ 10.1097/PAS.0b013e31828d387b
131. Volante M, Bollito E, Sperone P, Tavaglione V, Daffara F, Porpiglia F, Terzolo M, Berruti A, Papotti M (2009) Clinico- pathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology 55:535-543 . https://doi.org/10. 1111/j.1365-2559.2009.03423.x
132. Pennanen M, Heiskanen I, Sane T, Remes S, Mustonen H, Haglund C, Arola J (2015) Helsinki score-a novel model for pre- diction of metastases in adrenocortical carcinomas. Hum Pathol 46:404-410 . https://doi.org/10.1016/j.humpath.2014.11.015
133. Duregon E, Cappellesso R, Maffeis V, Zaggia B, Ventura L, Berruti A, Terzolo M, Fassina A, Volante M, Papotti M (2017) Validation of the prognostic role of the “Helsinki Score” in 225 cases of adrenocortical carcinoma. Hum Pathol 62:1-7 . https:// doi.org/10.1016/j.humpath.2016.09.035
134. Fonseca D, Murthy SS, Tagore KR, Rao BV, Thamminedi SR, Raju KVVN, Sharma R, Challa S (2017) Diagnosis of Adreno- cortical Tumors by Reticulin Algorithm. Indian J Endocrinol Metab 21:734-737 . https://doi.org/10.4103/ijem.IJEM_573_16
135. Lin BT, Bonsib SM, Mierau GW, Weiss LM, Medeiros LJ (1998) Oncocytic adrenocortical neoplasms: a report of seven cases and review of the literature. Am J Surg Pathol 22:603-614 . https:// doi.org/10.1097/00000478-199805000-00012
136. Brondani VB, Lacombe AMF, Mariani BM de P, Montenegro L, Soares IC, Bezerra-Neto JE, Tanno FY, Srougi V, Chambo JL, Mendonca BB, Almeida MQ, Zerbini MCN, Fragoso MCBV (2021) Low Protein Expression of both ATRX and ZNRF3 as Novel Negative Prognostic Markers of Adult Adrenocortical Carcinoma. Int J Mol Sci 22:1238 . https://doi.org/10.3390/ijms22031238
137. Duan K, Gucer H, Kefeli M, Asa SL, Winer DA, Mete O (2020) Immunohistochemical Analysis of the Metabolic Phenotype of Adrenal Cortical Carcinoma. Endocr Pathol 31:231-238 . https:// doi.org/10.1007/s12022-020-09624-3
138. Duregon E, Volante M, Giorcelli J, Terzolo M, Lalli E, Papotti M (2013) Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. Hum Pathol 44:822-828 . https://doi. org/10.1016/j.humpath.2012.07.025
139. Martins-Filho SN, Almeida MQ, Soares I, Wakamatsu A, Alves VAF, Fragoso MCBV, Zerbini MCN (2021) Clinical Impact of Pathological Features Including the Ki-67 Labeling Index on Diagnosis and Prognosis of Adult and Pediatric Adrenocortical Tumors. Endocr Pathol 32:288-300 . https://doi.org/10.1007/ s12022-020-09654-x
140. Papathomas TG, Pucci E, Giordano TJ, Lu H, Duregon E, Volante M, Papotti M, Lloyd RV, Tischler AS, van Nederveen FH, Nose V, Erickson L, Mete O, Asa SL, Turchini J, Gill AJ, Matias-Guiu X, Skordilis K, Stephenson TJ, Tissier F, Feelders RA, Smid M, Nigg A, Korpershoek E, van der Spek PJ, Dinjens WNM, Stubbs AP, de Krijger RR (2016) An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. Am J Surg Pathol 40:569- 576 . https://doi.org/10.1097/PAS.0000000000000574
141. Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, Libé R, Ardito A, Al Ghuzlan A, Quinkler M, OBwald A, Ronchi CL, de Krijger R, Feelders RA, Waldmann J, Willenberg HS, Deutschbein T, Stell A, Reincke M, Papotti M, Baudin E, Tissier F, Haak HR, Loli P, Terzolo M, Allolio B, Müller H-H, Fassnacht
M (2015) Major prognostic role of Ki67 in localized adrenocorti- cal carcinoma after complete resection. J Clin Endocrinol Metab 100:841-849 . https://doi.org/10.1210/jc.2014-3182
142. Duregon E, Molinaro L, Volante M, Ventura L, Righi L, Bolla S, Terzolo M, Sapino A, Papotti MG (2014) Comparative diag- nostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocor- tical carcinoma. Mod Pathol 27:1246-1254 . https://doi.org/10. 1038/modpathol.2013.230
143. McAteer JP, Huaco JA, Gow KW (2013) Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemi- ology, and End Results (SEER) program study. J Pediatr Surg 48:1025-1031 . https://doi.org/10.1016/j.jpedsurg.2013.02.017
144. Pinto EM, Zambetti GP (2020) What 20 years of research has taught us about the TP53 p.R337H mutation. Cancer 126:4678- 4686 . https://doi.org/10.1002/cncr.33143
145. Ferreira AM, Brondani VB, Helena VP, Charchar HLS, Zerbini MCN, Leite LAS, Hoff AO, Latronico AC, Mendonca BB, Diz MDPE, de Almeida MQ, Fragoso MCBV (2019) Clinical spec- trum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation. J Ster- oid Biochem Mol Biol 190:250-255 . https://doi.org/10.1016/j. jsbmb.2019.04.011
146. Pinto EM, Zambetti GP, Rodriguez-Galindo C (2020) Pediatric adrenocortical tumours. Best Pract Res Clin Endocrinol Metab 34:101448 . https://doi.org/10.1016/j.beem.2020.101448
147. Stratakis CA (2008) Cushing syndrome caused by adrenocorti- cal tumors and hyperplasias (corticotropin- independent Cushing syndrome). Endocr Dev 13:117-132 . https://doi.org/10.1159/ 000134829
148. Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D (1994) High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 86:1707-1710 . https:// doi.org/10.1093/jnci/86.22.1707
149. Amadou A, Achatz MIW, Hainaut P (2018) Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol 30:23-29 . https://doi.org/10.1097/CCO.0000000000000423
150. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA (2003) Li-Fraumeni and related syndromes: correla- tion between tumor type, family structure, and TP53 genotype. Cancer Res 63:6643-6650
151. Else T (2012) Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol Cell Endocrinol 351:66-70 . https://doi.org/10.1016/j.mce.2011.12.008
152. Pinto EM, Chen X, Easton J, Finkelstein D, Liu Z, Pounds S, Rodriguez-Galindo C, Lund TC, Mardis ER, Wilson RK, Boggs K, Yergeau D, Cheng J, Mulder HL, Manne J, Jenkins J, Mastellaro MJ, Figueiredo BC, Dyer MA, Pappo A, Zhang J, Downing JR, Ribeiro RC, Zambetti GP (2015) Genomic land- scape of paediatric adrenocortical tumours. Nat Commun 6:6302 . https://doi.org/10.1038/ncomms7302
153. Dehner LP, Hill DA (2009) Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survi- vors? Pediatr Dev Pathol 12:284-291 . https://doi.org/10.2350/ 08-06-0489.1
154. Wieneke JA, Thompson LDR, Heffess CS (2003) Adrenal cor- tical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. Am J Surg Pathol 27:867-881 . https://doi.org/10.1097/00000478-200307000-00001
155. Picard C, Orbach D, Carton M, Brugieres L, Renaudin K, Aubert S, Berrebi D, Galmiche L, Dujardin F, Leblond P, Thomas-Teinturier C, Dijoud F (2019) Revisiting the role of the pathological grading in pediatric adrenal cortical tumors: results from a national cohort study with pathological review. Mod Pathol 32:546-559 . https:// doi.org/10.1038/s41379-018-0174-8
156. Lam AK-Y (2021) Adrenocortical Carcinoma: Updates of Clinical and Pathological Features after Renewed World Health Organisation Classification and Pathology Staging. Biomedicines 9:175 . https://doi.org/10.3390/biomedicines9020175
157. Michalkiewicz E, Sandrini R, Figueiredo B, Miranda ECM, Caran E, Oliveira-Filho AG, Marques R, Pianovski M a. D, Lacerda L, Cristofani LM, Jenkins J, Rodriguez-Galindo C, Ribeiro RC (2004) Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediat- ric Adrenocortical Tumor Registry. J Clin Oncol 22:838-845 . https://doi.org/10.1200/JCO.2004.08.085
158. Sandrini R, Ribeiro RC, DeLacerda L (1997) Childhood adreno- cortical tumors. J Clin Endocrinol Metab 82:2027-2031 . https:// doi.org/10.1210/jcem.82.7.4057
159. Gupta N, Rivera M, Novotny P, Rodriguez V, Bancos I, Lteif A (2018) Adrenocortical Carcinoma in Children: A Clinicopathologi- cal Analysis of 41 Patients at the Mayo Clinic from 1950 to 2017. Horm Res Paediatr 90:8-18 . https://doi.org/10.1159/000488855
160. Papotti M, Duregon E, Volante M, McNicol AM (2014) Pathol- ogy of the adrenal cortex: a reappraisal of the past 25 years focus- ing on adrenal cortical tumors. Endocr Pathol 25:35-48 . https:// doi.org/10.1007/s12022-013-9291-6
161. van Slooten H, Schaberg A, Smeenk D, Moolenaar AJ (1985) Morphologic characteristics of benign and malignant adrenocor- tical tumors. Cancer 55:766-773 . https://doi.org/10.1002/1097- 0142(19850215)55:4<766:aid-cncr2820550414>3.0.co;2-7
162. Hough AJ, Hollifield JW, Page DL, Hartmann WH (1979) Prog- nostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data. Am J Clin Pathol 72:390-399 . https://doi.org/10.1093/ajcp/72.3.390
163. Giordano TJ (2011) The argument for mitotic rate-based grading for the prognostication of adrenocortical carcinoma. Am J Surg Pathol 35:471-473 . https://doi.org/10.1097/PAS.0b013e31820bcf21
164. Mete O, Asa SL, Baker TP, Berman MA, Davis J, Erickson L, Giordano TJ, Rudzinski ER, Tischler A, Thompson LDR, Weiss LM (2021) College of American Pathologists (CAP) Protocol for the examination of specimens from patients with carcinoma of the adrenal gland. Version:4.2.1.0. Protocol Posting Date: Novem- ber 2021. https://www.cap.org/protocols-and-guidelines/cancer- reporting-tools/cancer-protocol-templates
165. Stojadinovic A, Brennan MF, Hoos A, Omeroglu A, Leung DHY, Dudas ME, Nissan A, Cordon-Cardo C, Ghossein RA (2003) Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis. Mod Pathol 16:742-751 . https://doi.org/10.1097/01.MP.0000081730.72305.81
166. Arola J, Salmenkivi K, Liu J, Kahri AI, Heikkilä P (2000) p53 and Ki67 in adrenocortical tumors. Endocr Res 26:861-865 . https://doi.org/10.3109/07435800009048609
167. Soon PSH, Gill AJ, Benn DE, Clarkson A, Robinson BG, McDonald KL, Sidhu SB (2009) Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer 16:573-583 . https://doi. org/10.1677/ERC-08-0237
168. Wachenfeld C, Beuschlein F, Zwermann O, Mora P, Fassnacht M, Allolio B, Reincke M (2001) Discerning malignancy in adreno- cortical tumors: are molecular markers useful? Eur J Endocrinol 145:335-341 . https://doi.org/10.1530/eje.0.1450335
169. Elhassan YS, Altieri B, Berhane S, Cosentini D, Calabrese A, Haissaguerre M, Kastelan D, Fragoso MCBV, Bertherat J, Al Ghuzlan A, Haak H, Boudina M, Canu L, Loli P, Sherlock M, Kimpel O, Laganà M, Sitch AJ, Kroiss M, Arlt W, Terzolo M, Berruti A, Deeks JJ, Libé R, Fassnacht M, Ronchi CL (2021) S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. Eur J Endocrinol 186:25-36 . https://doi.org/10.1530/EJE-21-0510
170. Cree IA (2022) From Counting Mitoses to Ki67 Assessment: Technical Pitfalls in the New WHO Classification of Endocrine and Neuroendocrine Tumors. Endocr Pathol. https://doi.org/10. 1007/s12022-021-09701-1
171. Cree IA, Tan PH, Travis WD, Wesseling P, Yagi Y, White VA, Lokuhetty D, Scolyer RA (2021) Counting mitoses: SI(ze) matters! Mod Pathol 34:1651-1657 . https://doi.org/10.1038/ s41379-021-00825-7
172. Faillot S, Foulonneau T, Néou M, Espiard S, Garinet S, Vaczlavik A, Jouinot A, Rondof W, Septier A, Drougat L, Hécale-Perlemoine K, Ragazzon B, Rizk-Rabin M, Sibony M, Bonnet-Serrano F, Guibourdenche J, Libé R, Groussin L, Dousset B, de Reyniès A, Bertherat J, Assié G (2021) Genomic classification of benign adrenocortical lesions. Endocr Relat Cancer 28:79-95 . https://doi. org/10.1530/ERC-20-0128
173. Mohan DR, Lerario AM, Else T, Mukherjee B, Almeida MQ, Vinco M, Rege J, Mariani BMP, Zerbini MCN, Mendonca BB, Latronico AC, Marie SKN, Rainey WE, Giordano TJ, Fragoso MCBV, Hammer GD (2019) Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma. Clin Can- cer Res 25:3276-3288 . https://doi.org/10.1158/1078-0432. CCR-18-2693
174. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G, Hammer G (2009) Molecu- lar classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 15:668-676 . https://doi. org/10.1158/1078-0432.CCR-08-1067
175. de Reyniès A, Assié G, Rickman DS, Tissier F, Groussin L, René-Corail F, Dousset B, Bertagna X, Clauser E, Bertherat J (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27:1108-1115 . https:// doi.org/10.1200/JCO.2008.18.5678
176. Mete O, Pakbaz S, Lerario AM, Giordano TJ, Asa SL (2021) Significance of Alpha-inhibin Expression in Pheochromocy- tomas and Paragangliomas. Am J Surg Pathol 45:1264-1273 . https://doi.org/10.1097/PAS.0000000000001715
177. Mete O, Asa SL (2020) Structure, Function, and Morphol- ogy in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors. Endocr Pathol 31:330-336 . https://doi.org/10.1007/ s12022-020-09646-x
178. Schmitt A, Saremaslani P, Schmid S, Rousson V, Montani M, Schmid DM, Heitz PU, Komminoth P, Perren A (2006) IGFII and MIB 1 immunohistochemistry is helpful for the differentia- tion of benign from malignant adrenocortical tumours. Histo- pathology 49:298-307 . https://doi.org/10.1111/j.1365-2559. 2006.02505.x
179. Domènech M, Grau E, Solanes A, Izquierdo A, Del Valle J, Carrato C, Pineda M, Dueñas N, Pujol M, Lázaro C, Capellà G, Brunet J, Navarro M (2021) Characteristics of Adrenocortical Carcinoma Associated With Lynch Syndrome. J Clin Endo- crinol Metab 106:318-325 . https://doi.org/10.1210/clinem/ dgaa833
180. Raymond VM, Everett JN, Furtado LV, Gustafson SL, Jungbluth CR, Gruber SB, Hammer GD, Stoffel EM, Greenson JK, Giordano TJ, Else T (2013) Adrenocortical carcinoma is a lynch syndrome- associated cancer. J Clin Oncol 31:3012-3018 . https://doi.org/10. 1200/JCO.2012.48.0988
181. Pozdeyev N, Fishbein L, Gay LM, Sokol ES, Hartmaier R, Ross JS, Darabi S, Demeure MJ, Kar A, Foust LJ, Koc K, Bowles DW, Leong S, Wierman ME, Kiseljak-Vassiliades K (2021) Targeted genomic analysis of 364 adrenocortical carcinomas. Endocr Relat Cancer 28:671-681 . https://doi.org/10.1530/ERC-21-0040
182. D’Avolio A, De Francia S, Basile V, Cusato J, De Martino F, Pirro E, Piccione F, Ardito A, Zaggia B, Volante M, Di Perri G, Terzolo M (2013) Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenet Genomics 23:293-300 . https://doi.org/10.1097/FPC.0b013e3283606cb2
183. Volante M, Terzolo M, Fassnacht M, Rapa I, Germano A, Sbiera S, Daffara F, Sperone P, Scagliotti G, Allolio B, Papotti M, Berruti A (2012) Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adreno- cortical cancer. Clin Cancer Res 18:3452-3461 . https://doi.org/ 10.1158/1078-0432.CCR-11-2692
184. Else T, Lerario AM, Everett J, Haymon L, Wham D, Mullane M, Wilson TL, Rainville I, Rana H, Worth AJ, Snyder NW, Blair IA, Mckay R, Kilbridge K, Hammer G, Barletta J, Vaidya A (2017) Adrenocortical carcinoma and succinate dehydrogenase gene mutations: an observational case series. Eur J Endocrinol 177:439-444 . https://doi.org/10.1530/EJE-17-0358
185. Williams TA, Monticone S, Schack VR, Stindl J, Burrello J, Buffolo F, Annaratone L, Castellano I, Beuschlein F, Reincke M, Lucatello B, Ronconi V, Fallo F, Bernini G, Maccario M, Giacchetti G, Veglio F, Warth R, Vilsen B, Mulatero P (2014) Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone- producing adenomas. Hypertension 63:188-195 . https://doi.org/ 10.1161/HYPERTENSIONAHA.113.01733
186. Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Åkerström G, Wang W, Carling T, Lifton RP (2011) K+ channel mutations in adrenal aldosterone- producing adenomas and hereditary hypertension. Science 331:768- 772 . https://doi.org/10.1126/science.1198785
187. Nanba K, Yamazaki Y, Bick N, Onodera K, Tezuka Y, Omata K, Ono Y, Blinder AR, Tomlins SA, Rainey WE, Satoh F, Sasano H (2020) Prevalence of Somatic Mutations in Aldosterone-Producing Adenomas in Japanese Patients. J Clin Endocrinol Metab 105. https:/ doi.org/10.1210/clinem/dgaa595
188. Azizan EAB, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W, Shaikh LH, Brighton CA, Teo AED, Davenport AP, Dekkers T, Tops B, Küsters B, Ceral J, Yeo GSH, Neogi SG, McFarlane I, Rosenfeld N, Marass F, Hadfield J, Margas W, Chaggar K, Solar M, Deinum J, Dolphin AC, Farooqi IS, Striessnig J, Nissen P, Brown MJ (2013) Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 45:1055- 1060 . https://doi.org/10.1038/ng.2716
189. Scholl UI, Goh G, Stölting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW, Prasad ML, Hartung EA, Mauras N, Benson MR, Brady T, Shapiro JR, Loring E, Nelson-Williams C, Libutti SK, Mane S, Hellman P, Westin G, Åkerström G, Björklund P, Carling T, Fahlke C, Hidalgo P, Lifton RP (2013) Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet 45:1050-1054 . https:// doi.org/10.1038/ng.2695
190. Nanba K, Blinder AR, Rege J, Hattangady NG, Else T, Liu C-J, Tomlins SA, Vats P, Kumar-Sinha C, Giordano TJ, Rainey WE (2020) Somatic CACNA1H Mutation As a Cause of Aldosterone- Producing Adenoma. Hypertension 75:645-649 . https://doi.org/ 10.1161/HYPERTENSIONAHA.119.14349
191. Scholl UI, Stölting G, Nelson-Williams C, Vichot AA, Choi M, Loring E, Prasad ML, Goh G, Carling T, Juhlin CC, Quack I, Rump LC, Thiel A, Lande M, Frazier BG, Rasoulpour M, Bowlin DL, Sethna CB, Trachtman H, Fahlke C, Lifton RP (2015) Recur- rent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife 4:e06315 . https://doi.org/10.7554/eLife.06315
192. Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, Penton D, Schack VR, Amar L, Fischer E, Walther A, Tauber P, Schwarzmayr T, Diener S, Graf E, Allolio B, Samson-Couterie B, Benecke A, Quinkler M, Fallo F, Plouin P-F, Mantero F, Meitinger T, Mulatero P, Jeunemaitre X, Warth R, Vilsen B, Zennaro M-C, Strom TM, Reincke M (2013) Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 45:440-444, 444e1-2 . https://doi.org/10.1038/ng.2550
193. Wannachalee T, Zhao L, Nanba K, Nanba AT, Shields JJ, Rainey WE, Auchus RJ, Turcu AF (2019) Three Discrete Patterns of Primary Aldosteronism Lateralization in Response to Cosyntro- pin During Adrenal Vein Sampling. J Clin Endocrinol Metab 104:5867-5876 . https://doi.org/10.1210/jc.2019-01182
194. Lenzini L, Rossitto G, Maiolino G, Letizia C, Funder JW, Rossi GP (2015) A Meta-Analysis of Somatic KCNJ5 K(+) Channel Mutations In 1636 Patients With an Aldosterone-Producing Adenoma. J Clin Endocrinol Metab 100:E1089-1095 . https:// doi.org/10.1210/jc.2015-2149
195. Azizan EAB, Lam BYH, Newhouse SJ, Zhou J, Kuc RE, Clarke J, Happerfield L, Marker A, Hoffman GJ, Brown MJ (2012) Microarray, qPCR, and KCNJ5 sequencing of aldosterone- producing adenomas reveal differences in genotype and phe- notype between zona glomerulosa- and zona fasciculata-like tumors. J Clin Endocrinol Metab 97:E819-829 . https://doi. org/10.1210/jc.2011-2965
196. Nanba K, Omata K, Gomez-Sanchez CE, Stratakis CA, Demidowich AP, Suzuki M, Thompson LDR, Cohen DL, Luther JM, Gellert L, Vaidya A, Barletta JA, Else T, Giordano TJ, Tomlins SA, Rainey WE (2019) Genetic Characteristics of Aldosterone-Producing Adenomas in Blacks. Hypertension 73:885-892 . https://doi.org/ 10.1161/HYPERTENSIONAHA.118.12070
197. Nanba K, Omata K, Else T, Beck PCC, Nanba AT, Turcu AF, Miller BS, Giordano TJ, Tomlins SA, Rainey WE (2018) Tar- geted Molecular Characterization of Aldosterone-Producing Adenomas in White Americans. J Clin Endocrinol Metab 103:3869-3876 . https://doi.org/10.1210/jc.2018-01004
198. Omata K, Anand SK, Hovelson DH, Liu C-J, Yamazaki Y, Nakamura Y, Ito S, Satoh F, Sasano H, Rainey WE, Tomlins SA (2017) Aldosterone-Producing Cell Clusters Frequently Harbor Somatic Mutations and Accumulate With Age in Normal Adrenals. J Endocr Soc 1:787-799 . https://doi.org/10.1210/js.2017-00134
199. Fernandes-Rosa FL, Giscos-Douriez I, Amar L, Gomez-Sanchez CE, Meatchi T, Boulkroun S, Zennaro M-C (2015) Different Somatic Mutations in Multinodular Adrenals With Aldosterone- Producing Adenoma. Hypertension 66:1014-1022 . https://doi. org/10.1161/HYPERTENSIONAHA.115.05993
200. Wu V-C, Wang S-M, Chueh S-CJ, Yang S-Y, Huang K-H, Lin Y-H, Wang J-J, Connolly R, Hu Y-H, Gomez-Sanchez CE, Peng K-Y, Wu K-D (2017) The prevalence of CTNNB1 mutations in primary aldosteronism and consequences for clinical outcomes. Sci Rep 7:39121 . https://doi.org/10.1038/srep39121
201. Åkerström T, Maharjan R, Sven Willenberg H, Cupisti K, Ip J, Moser A, Stålberg P, Robinson B, Alexander Iwen K, Dralle H, Walz MK, Lehnert H, Sidhu S, Gomez-Sanchez C, Hellman P, Björklund P (2016) Activating mutations in CTNNB1 in aldos- terone producing adenomas. Sci Rep 6:19546 . https://doi.org/ 10.1038/srep19546
202. Juhlin CC, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, Brown TC, Overton JD, Mane SM, Nelson- Williams C, Bäckdahl M, Suttorp A-C, Haase M, Choi M, Schlessinger J, Rimm DL, Höög A, Prasad ML, Korah R, Larsson C, Lifton RP, Carling T (2015) Whole-exome sequencing char- acterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J Clin Endocrinol Metab 100:E493-502 . https://doi.org/10.1210/jc.2014-3282
203. Bonnet S, Gaujoux S, Launay P, Baudry C, Chokri I, Ragazzon B, Libé R, René-Corail F, Audebourg A, Vacher-Lavenu M-C, Groussin L, Bertagna X, Dousset B, Bertherat J, Tissier F (2011) Wnt/ß-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. J Clin Endocrinol Metab 96:E419-426 . https://doi.org/10.1210/jc.2010-1885
204. Tadjine M, Lampron A, Ouadi L, Bourdeau I (2008) Frequent mutations of beta-catenin gene in sporadic secreting adrenocorti- cal adenomas. Clin Endocrinol (Oxf) 68:264-270 . https://doi. org/10.1111/j.1365-2265.2007.03033.x
205. Berthon A, Drelon C, Ragazzon B, Boulkroun S, Tissier F, Amar L, Samson-Couterie B, Zennaro M-C, Plouin P-F, Skah S, Plateroti M, Lefèbvre H, Sahut-Barnola I, Batisse-Lignier M, Assié G, Lefrançois- Martinez A-M, Bertherat J, Martinez A, Val P (2014) WNT/B- catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Hum Mol Genet 23:889-905 . https://doi.org/10.1093/hmg/ddt484
206. Espiard S, Knape MJ, Bathon K, Assié G, Rizk-Rabin M, Faillot S, Luscap-Rondof W, Abid D, Guignat L, Calebiro D, Herberg FW, Stratakis CA, Bertherat J (2018) Activating PRKACB somatic mutation in cortisol-producing adenomas. JCI Insight 3. https://doi. org/10.1172/jci.insight.98296
207. Thiel A, Reis A-C, Haase M, Goh G, Schott M, Willenberg HS, Scholl UI (2015) PRKACA mutations in cortisol-producing adeno- mas and adrenal hyperplasia: a single-center study of 60 cases. Eur J Endocrinol 172:677-685 . https://doi.org/10.1530/EJE-14-1113
208. Di Dalmazi G, Kisker C, Calebiro D, Mannelli M, Canu L, Arnaldi G, Quinkler M, Rayes N, Tabarin A, Laure Jullié M, Mantero F, Rubin B, Waldmann J, Bartsch DK, Pasquali R, Lohse M, Allolio B, Fassnacht M, Beuschlein F, Reincke M (2014) Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing’s syndrome: a European multicentric study. J Clin Endocrinol Metab 99:E2093- 2100 . https://doi.org/10.1210/jc.2014-2152
209. Sato Y, Maekawa S, Ishii R, Sanada M, Morikawa T, Shiraishi Y, Yoshida K, Nagata Y, Sato-Otsubo A, Yoshizato T, Suzuki H, Shiozawa Y, Kataoka K, Kon A, Aoki K, Chiba K, Tanaka H, Kume H, Miyano S, Fukayama M, Nureki O, Homma Y, Ogawa S (2014) Recurrent somatic mutations underlie corticotropin- independent Cushing’s syndrome. Science 344:917-920 . https:// doi.org/10.1126/science.1252328
210. Goh G, Scholl UI, Healy JM, Choi M, Prasad ML, Nelson-Williams C, Kunstman JW, Kuntsman JW, Korah R, Suttorp A-C, Dietrich D, Haase M, Willenberg HS, Stålberg P, Hellman P, Akerström G, Björklund P, Carling T, Lifton RP (2014) Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat Genet 46:613-617 . https://doi.org/10.1038/ng.2956
211. Beuschlein F, Fassnacht M, Assié G, Calebiro D, Stratakis CA, Osswald A, Ronchi CL, Wieland T, Sbiera S, Faucz FR, Schaak K, Schmittfull A, Schwarzmayr T, Barreau O, Vezzosi D, Rizk-Rabin M, Zabel U, Szarek E, Salpea P, Forlino A, Vetro A, Zuffardi O, Kisker C, Diener S, Meitinger T, Lohse MJ, Reincke M, Bertherat J, Strom TM, Allolio B (2014) Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome. N Engl J Med 370:1019-1028 . https://doi.org/10.1056/NEJMoa1310359
212. Bertherat J, Groussin L, Sandrini F, Matyakhina L, Bei T, Stergiopoulos S, Papageorgiou T, Bourdeau I, Kirschner LS, Vincent-Dejean C, Perlemoine K, Gicquel C, Bertagna X, Stratakis CA (2003) Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res 63:5308-5319
213. Sheekey E, Narita M (2021) p53 in senescence - it’s a marathon not a sprint. FEBS J. https://doi.org/10.1111/febs.16325
214. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238 . https://doi.org/ 10.1126/science.1978757
215. Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, René-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, Papathomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F, Libé R, de Reyniès A, Bertherat J (2014) Integrated genomic characterization of adreno- cortical carcinoma. Nat Genet 46:607-612 . https://doi.org/10. 1038/ng.2953
216. de Krijger RE, Bertherat J (2016) 5th International ACC Sympo- sium: Classification of Adrenocortical Cancers from Pathology to Integrated Genomics: Real Advances or Lost in Translation? Horm Cancer 7:3-8 . https://doi.org/10.1007/s12672-015-0242-1
217. Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F, Le Bouc Y (1994) Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 78:1444-1453 . https://doi.org/10.1210/jcem.78.6.7911125
218. Henry I, Jeanpierre M, Couillin P, Barichard F, Serre JL, Journel H, Lamouroux A, Turleau C, de Grouchy J, Junien C (1989) Molecular definition of the 11p15.5 region involved in Beckwith- Wiedemann syndrome and probably in predisposition to adreno- cortical carcinoma. Hum Genet 81:273-277 . https://doi.org/10. 1007/BF00279003
219. Sasaki H, Ishihara K, Kato R (2000) Mechanisms of Igf2/H19 imprinting: DNA methylation, chromatin and long-distance gene regulation. J Biochem 127:711-715 . https://doi.org/10.1093/ oxfordjournals.jbchem.a022661
220. Barreau O, Assié G, Wilmot-Roussel H, Ragazzon B, Baudry C, Perlemoine K, René-Corail F, Bertagna X, Dousset B, Hamzaoui N, Tissier F, de Reynies A, Bertherat J (2013) Identification of a CpG island methylator phenotype in adrenocortical carcinomas. J Clin Endocrinol Metab 98:E174-184 . https://doi.org/10.1210/ jc.2012-2993
221. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin P-F, Baudin E, Berger F, Gicquel C, Chabre O, Feige J-J (2005) Gene expres- sion profiling of human adrenocortical tumors using comple- mentary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90:1819-1829 . https://doi.org/10.1210/jc.2004-1075
222. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson NW, Taylor JMG, Hanash SM (2003) Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analy- sis. Am J Pathol 162:521-531 . https://doi.org/10.1016/S0002- 9440(10)63846-1
223. Assié G, Jouinot A, Fassnacht M, Libé R, Garinet S, Jacob L, Hamzaoui N, Neou M, Sakat J, de La Villéon B, Perlemoine K, Ragazzon B, Sibony M, Tissier F, Gaujoux S, Dousset B, Sbiera S, Ronchi CL, Kroiss M, Korpershoek E, De Krijger R, Waldmann J, Quinkler M, Haissaguerre M, Tabarin A, Chabre O, Luconi M, Mannelli M, Groussin L, Bertagna X, Baudin E, Amar L, Coste J, Beuschlein F, Bertherat J (2019) Value of Molecu- lar Classification for Prognostic Assessment of Adrenocortical Carcinoma. JAMA Oncol 5:1440-1447 . https://doi.org/10.1001/ jamaoncol.2019.1558
224. Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, Arlt W, Auchus RJ, Falhammar H, Flück CE, Guasti L, Huebner A, Kortmann BBM, Krone N, Merke DP, Miller WL, Nordenström A, Reisch N, Sandberg DE, Stikkelbroeck NMML, Touraine P, Utari A, Wudy SA, White PC (2022) Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management. Endocr Rev 43:91-159 . https://doi.org/10. 1210/endrev/bnab016
225. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HFL, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC (2010) A Summary of the Endocrine Society Clinical Practice Guidelines on Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase Deficiency. Int J Pediatr Endocrinol 2010:494173 . https://doi.org/10.1155/2010/494173
226. Falhammar H, Wedell A, Nordenström A (2015) Biochemical and genetic diagnosis of 21-hydroxylase deficiency. Endocrine 50:306-314 . https://doi.org/10.1007/s12020-015-0731-6
227. 228. Calissendorff J, Juhlin CC, Sundin A, Bancos I, Falhammar H (2021) Adrenal myelolipomas. Lancet Diabetes Endocrinol 9:767-775 . https://doi.org/10.1016/S2213-8587(21)00178-9
228. Nermoen I, Falhammar H (2020) Prevalence and Characteristics of Adrenal Tumors and Myelolipomas in Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis. Endocr Pract 26:1351-1365 . https://doi.org/10.4158/EP-2020-0058
229. Horvath A, Giatzakis C, Tsang K, Greene E, Osorio P, Boikos S, Libè R, Patronas Y, Robinson-White A, Remmers E, Bertherat J, Nesterova M, Stratakis CA (2008) A cAMP-specific phos- phodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex. Eur J Hum Genet 16:1245- 1253 . https://doi.org/10.1038/ejhg.2008.85
230. Horvath A, Giatzakis C, Robinson-White A, Boikos S, Levine E, Griffin K, Stein E, Kamvissi V, Soni P, Bossis I, de Herder W, Carney JA, Bertherat J, Gregersen PK, Remmers EF, Stratakis CA (2006) Adrenal hyperplasia and adenomas are associated with inhi- bition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population. Cancer Res 66:11571- 11575 . https://doi.org/10.1158/0008-5472.CAN-06-2914
231. Ise T, Shimoda A, Takakuwa H, Kato T, Izumiya Y, Shimizu K, Suzuki T, Sasano H, Yokoyama H, Kobayashi K (2001) A chi- meric CYP11B1/CYP11B2 gene in glucocorticoid-insuppressible familial hyperaldosteronism. Clin Endocrinol (Oxf) 55:131-134 . https://doi.org/10.1046/j.1365-2265.2001.01192.x
232. Scholl UI, Stölting G, Schewe J, Thiel A, Tan H, Nelson-Williams C, Vichot AA, Jin SC, Loring E, Untiet V, Yoo T, Choi J, Xu S, Wu A, Kirchner M, Mertins P, Rump LC, Onder AM, Gamble C, McKenney D, Lash RW, Jones DP, Chune G, Gagliardi P, Choi M, Gordon R, Stowasser M, Fahlke C, Lifton RP (2018) CLCN2 chloride channel mutations in familial hyperaldoster- onism type II. Nat Genet 50:349-354 . https://doi.org/10.1038/ s41588-018-0048-5
233. Else T, Rodriguez-Galindo C (2016) 5th International ACC Sym- posium: Hereditary Predisposition to Childhood ACC and the Associated Molecular Phenotype: 5th International ACC Sympo- sium Session: Not Just for Kids! Horm Cancer 7:36-39 . https:// doi.org/10.1007/s12672-015-0244-z
234. Morin E, Mete O, Wasserman JD, Joshua AM, Asa SL, Ezzat S (2012) Carney complex with adrenal cortical carcinoma. J Clin Endo- crinol Metab 97:E202-206 . https://doi.org/10.1210/jc.2011-2321
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Authors and Affiliations
Ozgur Mete1,2,3 (D . Lori A. Erickson4(D . C. Christofer Juhlin5,6D . Ronald R. de Krijger7 D . Hironobu Sasano&D. Marco Volante(D . Mauro G. Papotti10D
☒ Ozgur Mete ozgur.mete2@uhn.ca
1 Department of Pathology, University Health Network, Toronto, ON, Canada
2 Endocrine Oncology Site, Princess Margaret Cancer Centre, Toronto, ON, Canada
3 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
4 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
5 Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
6 Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden
7 Princess Maxima Center for Pediatric Oncology, and Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
8 Department of Pathology, Tohoku University School of Medicine, Sendai, Japan
9 Department of Pathology, University of Turin, Turin, Italy
10 Department of Oncology, University of Turin, Turin, Italy